Articles de revues : « NCR Corporation »

1

Long, Henery F. « Bank and corporation Taxes in Massachusetts ». National Municipal Review 14, n^o 8 (5 janvier 2007) : 470–73. http://dx.doi.org/10.1002/ncr.4110140802.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Agarwal, Juhi, Chandrakant S. Pandav, Madhukar G. Karmarkar et Sirimavo Nair. « Community monitoring of the National Iodine Deficiency Disorders Control Programme in the National Capital Region of Delhi ». Public Health Nutrition 14, n^o 5 (1 mars 2010) : 754–57. http://dx.doi.org/10.1017/s1368980010000297.

Texte intégral

Résumé :

AbstractObjectiveThe present study was conducted to assess the current status of iodine-deficiency disorders (IDD) in the National Capital Region of Delhi (NCR Delhi) and evaluate the implementation and impact of the National Iodine Deficiency Disorders Control Programme (NIDDCP).DesignCross-sectional study.SettingSchool-going children (n1230) in the age group of 6–12 years were enrolled from thirty primary schools in the Municipal Corporation of Delhi. Thirty schools were selected using the probability-proportional-to-size cluster sampling methodology. In each identified school forty-one children were surveyed. Urine and salt samples were collected and studied for iodine concentration. A total of sixty salt samples from retail level were also collected.SubjectsSchoolchildren aged 6–12 years.ResultsThe median urinary iodine excretion (UIE) was found to be 198·4 μg/l. The percentage of children with UIE levels of <20·0, 20·0–49·9, 50·0–99·9 and ≥100·0 μg/l was 1·9, 4·3, 9·5 and 84·2 %, respectively. The proportion of households consuming adequately iodized salt (salt with iodine levels of at least 15 ppm at consumption level) was 88·8 %. The assessment of iodine content of salt revealed that only 6·1 % of the families were consuming salt with iodine content less than 7 ppm. At retail level 88·3 % of salt samples had >15 ppm iodine.ConclusionsSignificant progress has been achieved towards elimination of IDD from NCR Delhi. There is a need for further strengthening of the system to monitor the quality of iodized salt provided to the beneficiaries under the universal salt iodization programme and so eliminate IDD from NCR Delhi.

Styles APA, Harvard, Vancouver, ISO, etc.

3

Gautam, Neeraj. « A Study of Financial Planning on Young Individuals in Delhi NCR ». INTERANTIONAL JOURNAL OF SCIENTIFIC RESEARCH IN ENGINEERING AND MANAGEMENT 08, n^o 05 (12 mai 2024) : 1–5. http://dx.doi.org/10.55041/ijsrem33889.

Texte intégral

Résumé :

This research paper investigates the significance of financial planning for young individuals in achieving long-term financial security and stability. With the increasing complexity of the financial landscape and the challenges posed by economic uncertainties, effective financial planning is indispensable for the younger generation. The paper examines various strategies and tools available for young individuals to manage their finances prudently, including budgeting, saving, investing, and debt management. Additionally, it explores the role of financial education and literacy in empowering young people to make informed decisions about their finances. Through a comprehensive review of existing literature and case studies, this paper highlights the importance of early financial planning in building wealth, mitigating risks, and achieving financial goals. Furthermore, it discusses the potential barriers and challenges faced by young individuals in implementing financial plans, such as student loans, low income, and lack of knowledge. Finally, the paper offers practical recommendations and actionable insights for young individuals to enhance their financial well-being and lay a strong foundation for a secure financial future. Monetary items function as a venture route, providing the financial supporters with the predefined monetary security and upholding the monetary items' gamble return profile. In the past traditionally, In India, banks (credit and store accounts), the Life Insurance Corporation (LIC), and the Post Office (repeating shop, National Saving Certificate, Kisan Vikas Patra) all displayed financial products. However, in recent times, as the financial services sector has advanced, new financial products have been introduced, including common stocks, shares, subordinates, annuity plans, children's education plans, life and non-extra security plans (Unit Linked Investment Plans, or ULIPs), common assets, and shares. Each person behaves differently when contributing, therefore each has a different predisposition towards speculation. A private person's investment behavior is influenced by his own circumstances. With the presumption of producing yields people invest in a few financial goods with the hope of earning sizable returns over time and with varying degrees of risk. The goal of the current analysis is to examine how salaried individuals speculate about financial goods that are supported by various segment elements.

Styles APA, Harvard, Vancouver, ISO, etc.

4

Verma, Rajanikant, et Nisha Bajaj. « COMPARATIVE STUDY ON PRIVATE & ; PUBLIC SECTOR BANK’S EMPLOYEES OF DELHI -NCR WITH RESPECT TO EUSTRESS MANAGEMENT ». Sachetas 1, n^o 3 (4 juillet 2022) : 60–67. http://dx.doi.org/10.55955/130006.

Texte intégral

Résumé :

Usually, the stress symbolises the negative meaning as it is that mental pressure & emotional instability which overpower an individual’s intellectual ability & critical thinking. This impacts their physical & mental health which in turn leads to inefficiency in accomplishment of organisational goals. Here, there is a need to shift in a perception from a negative stress to positive stress. The concept of Eustress becomes important in the present competitive era. It acts as a force that drives & stimulates the employees to fulfil the organisational goals along with their own holistic growth. This is an exploratory study which aims to determine that how public sector & private sector bank employees perceives the circumstances that causes stress and to identify the effect of eustress on job satisfaction & organisational commitment. In this study, the primary data have been collected by using questionnaire method which had given to the employees of four banks in Delhi-NCR named as: State Bank of India (SBI), Punjab National Bank (PNB), Kotak Mahindra Bank, Housing Development Finance Corporation Limited (HDFC) Bank i. e. two each from public sector and private sector banks. In this study, a total of 250 bank employees are as respondents, both from public & private sector banks. The various statistical tools have been used to test the hypothesis. The study concludes that pressure to complete task on time, increase in competence along with conscious efforts to reduce costs; job insecurity and internal competition will encourage the employees to enhance their capabilities & develop necessary skills for promotion & various other incentives.

Styles APA, Harvard, Vancouver, ISO, etc.

5

San Miguel, Jesús F., Vânia TM Hungria, Sung-Soo Yoon, Meral Beksac, Meletios A. Dimopoulos, Ashraf Elghandour, Wieslaw W. Jedrzejczak et al. « Analysis of Outcomes Based on Response in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma Treated with Panobinostat or Placebo in Combination with Bortezomib and Dexamethasone in the Panorama 1 Trial : Updated Analysis Based on Prior Treatment ». Blood 126, n^o 23 (3 décembre 2015) : 4230. http://dx.doi.org/10.1182/blood.v126.23.4230.4230.

Texte intégral

Résumé :

Abstract Introduction: Panobinostat (PAN), a potent pan-deacetylase inhibitor, was the first agent of its class to produce a statistically significant and clinically meaningful increase in the median progression-free survival (PFS) of patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM) in a phase 3 trial. In the PANORAMA 1 trial, the addition of PAN to treatment with bortezomib (BTZ) and dexamethasone (Dex; PAN-BTZ-Dex) led to a significant increase in high-quality responses (near-complete response/complete response [nCR/CR]; 27.6%) vs treatment with placebo (Pbo), BTZ, and Dex (15.7%; P = .00006). Pts in the PAN-BTZ-Dex arm also had a significantly prolonged median PFS of 12.0 months vs 8.1 months in pts treated with Pbo-BTZ-Dex (hazard ratio [HR], 0.63; P < .0001). Further, subgroup analysis showed that the PFS benefit was maintained in pts with previous exposure to BTZ and immunomodulatory drugs (IMiDs; 10.6 vs 5.8 months; HR, 0.52). These results supported the recent US FDA approval of PAN in combination with BTZ and Dex for the treatment of pts with relapsed or relapsed and refractory MM who have received ≥ 2 prior regimens including BTZ and an IMiD. Here, we present a detailed analysis of the effect of response on clinical outcomes in a subpopulation of PANORAMA 1 pts with prior exposure to BTZ and IMiDs. Methods: Response outcomes were analyzed for the subgroup of PANORAMA 1 pts with prior exposure to BTZ and IMiDs based on modified European Society for Blood and Marrow Transplantation criteria, including nCR/CR and partial response (PR). A landmark analysis at 12, 18, and 24 weeks was performed using a Cox regression model to assess the median PFS in pts who achieved nCR/CR and PR. Results: Among pts with prior exposure to BTZ and IMiDs, the nCR/CR rate was higher in the PAN-BTZ-Dex arm (22.3% [95% CI, 14.4-32.1]) vs the Pbo-BTZ-Dex arm (9.9% [95% CI, 4.2-16.6]). In the PAN-BTZ-Dex arm, the landmark analysis at 12 weeks demonstrated a median PFS of 13.7 months in pts achieving nCR/CR vs 8.1 months in pts achieving PR (HR, 0.34 [95% CI, 0.12-0.96]). Similarly, pts achieving nCR/CR in the Pbo-BTZ-Dex arm had a median PFS of 12.2 vs 7.8 months for pts achieving a PR (HR, 0.74 [95% CI, 0.27-2.01]). Landmark analysis at 18 weeks demonstrated a median PFS of 15.8 months for pts with nCR/CR vs 10.3 months for pts with a PR in the PAN arm (HR, 0.30 [95% CI, 0.12-0.75]) and 14.1 vs 9.0 months (HR, 0.76 [95% CI, 0.29-1.98]) in the Pbo arm for pts with nCR/CR and PR, respectively. The 24 week landmark assessment revealed a median PFS in the PAN arm of 15.8 months for pts with nCR/CR vs 13.7 months for pts with PR (HR, 0.32 [95% CI, 0.14-0.74]) and, in the Pbo arm, a median PFS of 12.2 months for pts with nCR/CR vs 11.2 months in pts with PR (HR, 0.93 [95% CI, 0.36-2.43]). Conclusions: Treatment with PAN-BTZ-Dex is associated with a > 2-fold increase in the rate of nCR/CR in pts with relapsed or relapsed and refractory MM compared with control arm. Among study pts who had received prior treatment with BTZ + IMiDs, those who achieved nCR/CR after treatment with PAN-BTZ-Dex demonstrated a prolonged PFS compared to pts who achieved PR.These data highlight the importance of achieving deep responses with PAN-BTZ-Dex in this subpopulation, suggesting that the achievement of such responses may be linked to improved clinical outcomes. Disclosures San Miguel: Millennium: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Onyx: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; MSD: Membership on an entity's Board of Directors or advisory committees. Beksac:Janssen-Cilag: Consultancy, Speakers Bureau; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene: Consultancy, Speakers Bureau. Dimopoulos:Onyx: Honoraria; Novartis: Honoraria; Amgen: Honoraria; Genesis: Honoraria; Janssen-Cilag: Honoraria; Celgene: Honoraria; Janssen: Honoraria. Jedrzejczak:Pfizer: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Onconova: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees. Siritanaratkul:Pfizer: Research Funding; Roche: Research Funding; Novartis: Research Funding; Janssen-Cilag: Research Funding. Schlossman:Millennium: Consultancy. Hou:Novartis: Membership on an entity's Board of Directors or advisory committees. Moreau:Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Millennium: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen-Cilag: Honoraria, Membership on an entity's Board of Directors or advisory committees. Lonial:Bristol-Myers Squibb: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; Onyx: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Millennium: Consultancy, Research Funding; Janssen: Consultancy, Research Funding. Einsele:Janssen: Consultancy, Honoraria, Research Funding, Speakers Bureau; Celgene: Consultancy, Honoraria, Research Funding, Speakers Bureau; Novartis: Consultancy, Honoraria, Research Funding, Speakers Bureau; Amgen/Onyx: Consultancy, Honoraria, Research Funding, Speakers Bureau. Sopala:Novartis Pharma: Employment, Equity Ownership. Bengoudifa:Novartis: Employment. Corrado:Novartis: Employment, Equity Ownership. Binlich:Novartis: Employment. Richardson:Millennium Takeda: Membership on an entity's Board of Directors or advisory committees; Gentium S.p.A.: Membership on an entity's Board of Directors or advisory committees, Research Funding; Jazz Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees; Celgene Corporation: Membership on an entity's Board of Directors or advisory committees.

Styles APA, Harvard, Vancouver, ISO, etc.

6

Gómez-Jara Díez, Carlos. « Corporate Culpability as a Limit to the Overcriminalization of Corporate Criminal Liability : The Interplay Between Self-Regulation, Corporate Compliance, and Corporate Citizenship ». New Criminal Law Review 14, n^o 1 (1 janvier 2011) : 78–96. http://dx.doi.org/10.1525/nclr.2011.14.1.78.

Texte intégral

Résumé :

This paper argues that there is clear sign of the overcriminalization of corporate conduct in America's criminal law and procedure: regardless of the evidence of a law-abiding behavior by a good corporate citizen, the corporation will be considered guilty if a member of its organization commits a crime within the scope of authority and with the intent to benefit the corporation. The paper explains that corporate culpability may function as a limit to this current overcriminalization as it demands in corporate criminal law what is requested in individual criminal law: that despite the agent's action and intent, the principal has not exercised some kind of due diligence. In turn, if evidence of that corporate due diligence is provided, no court should declare that a corporation is guilty. Such an approach is not only consistent with the basic tenets of criminal law, but it also reflects the different rationale for holding corporations criminally liable in modern society (as opposed to the times in which corporate criminal liability was enacted). A recent example of this overcriminalization tendency was provided by the 2nd Circuit's ruling in the case United States v. Ionia Management S.A., which is briefly discussed at the end of the paper.

Styles APA, Harvard, Vancouver, ISO, etc.

7

Prabhat, Saumya, et David M. Primo. « Risky business : Do disclosure and shareholder approval of corporate political contributions affect firm performance ? » Business and Politics 21, n^o 2 (27 décembre 2018) : 205–39. http://dx.doi.org/10.1017/bap.2018.24.

Texte intégral

Résumé :

AbstractThe role of corporations in the U.S. political process has received increased scrutiny in the wake of the U.S. Supreme Court'sCitizens Uniteddecision, leading to calls for greater regulation. In this paper, we analyze whether policies mandating greater disclosure and shareholder approval of political contributions reduce risk and increase firm value, as proponents of such rules claim. Specifically, we examine the Neill Committee Report (NCR), which led to the passage of the United Kingdom's Political Parties, Elections, and Referendums Act 2000 mandating new disclosure and shareholder approval rules. We find that politically active firms did not benefit from the NCR in the days after its release and suffered a decline in value in the months and years that followed. Politically active firms also suffered an increase in risk, as proxied by stock return volatility, following the release of the NCR. We theorize that these findings are due to the reduced flexibility these rules impose on corporate strategy as well as the potential for these rules to facilitate political activism against corporations.

Styles APA, Harvard, Vancouver, ISO, etc.

8

Jakubowiak, Andrzej J., Dominik Dytfeld, Sundar Jagannath, David H. Vesole, Tara B. Anderson, Brian K. Nordgren, Kristen Detweiler-Short et al. « Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM) ». Blood 118, n^o 21 (18 novembre 2011) : 631. http://dx.doi.org/10.1182/blood.v118.21.631.631.

Texte intégral

Résumé :

Abstract Abstract 631 Introduction: In relapsed and/or refractory MM, the combination of carfilzomib (CFZ) with lenalidomide (Len), and low-dose dexamethasone (Dex) (CRd) has shown very promising efficacy (78% ≥partial response [PR], 40% ≥very good partial response [VGPR], and 24% CR/nCR) and good tolerability including a low rate of peripheral neuropathy (Wang et al, ASCO, 2011). In a Phase I/II study of newly diagnosed MM, the regimen was well tolerated in the Phase I portion of the study up to a maximum dose of CFZ 36 mg/m2, Len 25 mg, and Dex 40 mg, and very active with 96% ≥PR, 70% ≥VGPR, and 55% CR/nCR (Jakubowiak et al, ASH 2010). The lack of overlapping toxicities has allowed these agents to be used at full doses and for extended periods. Here we report the results for all patients (pts) enrolled in both phases of this first prospective trial of CFZ combination in new MM. Methods: In the initial eight 28-day cycles, pts were treated with CFZ at 20 mg/m2, 27 mg/m2 (Phase I), and 36 mg/m2 (Phase I and II), given IV on days 1, 2, 8, 9, 15 and 16, Len at 25 mg PO (days 1–21), and Dex at 40/20 mg PO weekly (cycles 1–4/5–8). Pts achieving ≥PR could proceed to stem cell collection (SCC) using growth factors alone (protocol recommendation) and autologous stem cell transplant (ASCT) after 4 cycles. Per protocol, ASCT candidates were offered the option to continue CRd treatment after SCC. After 8 cycles, pts received 28-day maintenance cycles of CFZ (days 1, 2, 15, 16), Len days 1–21, and Dex weekly at the doses tolerated at the end of 8 cycles. Responses were assessed by IMWG criteria with the addition of nCR. Results: Enrollment was completed (53 pts): 4 pts at CFZ 20 mg/m2, 13 at CFZ 27 mg/m2 and 36 at CFZ 36 mg/m2 (18 in Phase I and 18 in Phase II). Median age was 59 years (range 35–81; 23 pts ≥65), 60% had ISS stage II/III, and 33% (of 49 with available data) had unfavorable cytogenetics: del 13 or hypodiploidy by metaphase, or t(4;14), t (14;16), del 17p by FISH. As of June 30, 2011, toxicity data (cycles 1–8) were available for 51 pts. Hematologic toxicities were reversible and included Grade (G) 3/4: anemia (18%), neutropenia (12%), and thrombocytopenia (10%). The most common non-hematologic toxicities (all G) were hyperglycemia (76%), hypophosphatemia (61%), and infection (53%). G3/4 non-hematologic AEs included hyperglycemia (24%), DVT/PE while on ASA prophylaxis (10%), infection (6%), and mood alteration (2%). PN was limited to G1/2 sensory (24%). Forty-five pts continue treatment with 22 pts in the maintenance phase. Six pts discontinued treatment: 2 proceeded to ASCT, 1 due to toxicity, and 3 due to events unrelated to treatment or per pt wish. The majority of pts did not require dose modifications, either in the initial (31%) or in the maintenance (25%) phase. After a median of 8 cycles (range 1–20), the best responses per IMWG criteria for 49 response-evaluable pts (all pts who completed 1+ cycle) are shown in the Table. Responses were rapid with 46/49 pts achieving at least PR after 1 cycle, and improved with the duration of treatment reaching 100% ≥PR after 4 cycles and 100% ≥VGPR, 79% CR/nCR after 12 cycles. Responses were deep even at the 2 lower dose levels with the majority of pts at 36 mg/m2 still early in treatment. Responses in pts with unfavorable cytogenetics were similar to response rates in all remaining pts and included a 100% ≥PR in 6 pts with del 17p. Twenty-four pts proceeded to SCC after a median of 5 cycles of CRd (range 4–9); using growth factors only in 23 pts and cyclophosphamide and growth factors in 1 pt, with a median 6.55 × 106 CD34+ cells/kg collected (range 3.75–9.6); all resumed CRd treatment. After a median of 9.5 months of follow-up, only 1 pt has progressed, and all are alive Conclusions: CRd is highly active and well-tolerated allowing the use of full doses for an extended time in newly-diagnosed MM pts with limited need for dose modification. Responses are rapid and improve over time reaching 100% ≥VGPR and early time-to-event data are very encouraging. These results compare favorably to the best frontline regimens in MM. Disclosures: Jakubowiak: Bristol-Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Onyx Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees; Millennium Pharmaceuticals, Inc.: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene: Consultancy, Honoraria, Speakers Bureau; Ortho Biotech: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Exelixis: Consultancy, Honoraria. Off Label Use: Use of the investigational agent carfilzomib, proteasome inhibitor, in the treatment of relapsed and/or refractory multiple myeloma. Jagannath:Millennium: Honoraria; Celgene: Honoraria; Onyx Pharmaceuticals: Honoraria; Merck: Honoraria; OrthoBiotec.Imedex: Membership on an entity's Board of Directors or advisory committees; Medicom World Wide: Membership on an entity's Board of Directors or advisory committees; Optum Health Education: Membership on an entity's Board of Directors or advisory committees; PER Group: Membership on an entity's Board of Directors or advisory committees. Vesole:Celgene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Millennium: Speakers Bureau. Hussein:Celgene Corporation: Employment. Leveque:Onyx Pharmaceuticals: Employment. Vij:Onyx Pharmaceuticals: Consultancy, Research Funding; Celgene: Research Funding, Speakers Bureau; Millennium: Speakers Bureau.

Styles APA, Harvard, Vancouver, ISO, etc.

9

Vidal, Avis C., et Bob Komives. « Community development corporations : A national perspective ». National Civic Review 78, n^o 3 (mai 1989) : 168–77. http://dx.doi.org/10.1002/ncr.4100780304.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

Jimenez-Zepeda, Victor H., Donna E. Reece, Suzanne Trudel, Christine Chen, Ahmed M. Rabea et Vishal Kukreti. « Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) for Heavily Pretreated Relapsed or Refractory Multiple Myeloma ». Blood 116, n^o 21 (19 novembre 2010) : 5028. http://dx.doi.org/10.1182/blood.v116.21.5028.5028.

Texte intégral

Résumé :

Abstract Abstract 5028 Lenalidomide (len) and bortezomib (btz) are active in multiple myeloma (MM). In preclinical studies, lenalidomide sensitized MM cells to bortezomib and dexamethasone (Mitsiades N, et al). The combination of lenalidomide (Revlimid), bortezomib (velcade), and dexamethasone (RVD) has shown excellent efficacy in relapsed/refractory (rel/ref) multiple myeloma (MM) patients (pts), with an overall response rate (ORR) of 84% and a partial response (PR) rate of 68%, including 21% complete/near complete responses (CR/nCR), median duration of response was 24 weeks in responding patients and median number of cycles was 6 (Anderson KC, et al. ASCO 2009: abstract 8536). The aim of this study is to assess the efficacy and toxicity profile when len is used in combination with btz and dexamethasone (dex) for pts with relapsed/refractory (rel/ref) disease outside the setting of clinical trials. Patients and Methods We retrospectively reviewed the records of all pts with rel/ref MM who were treated with RVD at Princess Margaret Hospital between March 2009 and March 2010. Eighteen pts were treated with at least 1 full cycle of RVD therapy given as len 10 mg/d on days 1–14, btz 1.0 or 1.3 mg/m2 on days 1, 4, 8, and 11 of 21-day cycles and dex (20 mg or 40 mg on days of and after btz). Pts routinely received concomitant antithrombotic and antiviral prophylaxis. Primary endpoints were response rate, time to progression (TTP) and toxicity. Responses were assessed according to modified EBMT and Uniform criteria. Toxicity was assessed using NCI-CTC, version 3.0. Results Clinical characteristics are seen in Table 1. Median age was 57 (37-71) years; 55% were female. The median number of prior therapies was 3 (2-6), and the majority of pts had already been treated with len (83%) and btz (78%) separately, and 77% had received both drugs previously but not in combination. In many instances, pts previously treated with len had len added to btz + dex at progression (n=5), or pts previously treated with btz had btz added to len + dex, at progression (n=4). After a median of 4.9 cycles (range 1–14), PR was observed in 7 (39%) and stable disease (SD) in 2 (11%) pts, for an ORR of 39%. Disease progression was seen in 14 pts at a median TTP of 4 months (1-13.6 months). Currently, 6 pts (33%) remain alive at a median F/U of 6.83 months (1.4-18.6 months). Median overall survival was 6.88 months (1-18.6 months) and six patients had a greater than 6 month response. Six pts have experienced grade 3/4 adverse events, including anemia, neutropenia, muscle weakness, hyperglycemia, and pneumonia. No deep vein thrombosis was observed. The side effect profile was manageable; importantly no patient experienced worsening of peripheral neuropathy. Conclusions The ORR for our heavily treated patient population was 39% which is lower than that reported by Anderson et al (ASCO, 2009). The median TTP was also short at 4 months. These differences can be partly explained by the fact the majority of our pts had previously received all the agents in RVD, while only 8% of the pts in the Anderson series had prior len exposure. These data suggest that the RVD combination can be effective in rel/ref MM, but responses/duration are affected by very advanced disease stage at relapse and the extent of prior treatment. Disclosures: Reece: Celgene: Honoraria, Research Funding. Chen:Celgene Corporation: Consultancy, Honoraria, Research Funding. Kukreti:Celgene: Honoraria.

Styles APA, Harvard, Vancouver, ISO, etc.

11

Abdullah, Ahsan. « City Corporation Election on Party Lines in Bangladesh : A Review of Narayanganj City Corporation (NCC) Election 2016 ». Public Affairs And Governance 5, n^o 1 (2017) : 73. http://dx.doi.org/10.5958/2321-2136.2017.00005.4.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

12

San Miguel, Jesus, Vania TM Hungria, Sung-Soo Yoon, Meral Beksac, Meletios A. Dimopoulos, Ashraf Elghandour, Wieslaw Wiktor Jedrzejczak et al. « Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study ». Blood 124, n^o 21 (6 décembre 2014) : 4742. http://dx.doi.org/10.1182/blood.v124.21.4742.4742.

Texte intégral

Résumé :

Abstract Introduction: Panobinostat (PAN) is a potent pan-deacetylase inhibitor (pan-DACi) that targets key aberrations in multiple myeloma (MM) cell biology, including protein metabolism and epigenetics. In a randomized phase 3 clinical trial in patients (pts) with relapsed or relapsed and refractory MM (PANORAMA 1), the addition of PAN to bortezomib (BTZ) and dexamethasone (Dex; PAN-BTZ-Dex) led to a clinically relevant and statistically significant increase in progression-free survival (PFS) of ≈ 4 months compared to placebo plus BTZ and Dex (Pbo-BTZ-Dex). PAN-BTZ-Dex was associated with a higher rate of adverse events (AEs) compared to Pbo-BTZ-Dex; however, a comparable number of pts completed the full duration of treatment on both treatment arms. Thus, we sought to determine the effect of treatment duration on the safety and efficacy of PAN-BTZ-Dex. Methods: The PANORAMA 1 trial consisted of two treatment phases (TP1 and TP2) with a maximum of 12 cycles total. In TP1 (eight 3-wk cycles), pts were randomized to receive oral PAN (20 mg) or Pbo administered three times a wk for the first 2 wks, and intravenous BTZ (1.3 mg/m2) administered on days 1, 4, 8, and 11 with Dex (20 mg) administered orally on the days of and after BTZ. Pts demonstrating clinical benefit could proceed to TP2 (four 6-wk cycles), in which PAN was administered on a similar schedule but BTZ was administered once-wkly (days 1, 8, 22 and 29) with Dex administered on the days of and after BTZ. This analysis focused on safety and efficacy specifically associated with the two treatment phases. For efficacy outcomes (PFS and near complete response/complete response [nCR/CR] rate), pt groups were delineated by those who received treatment > 8 cycles (completed TP1, 24 weeks) and all 12 cycles (completed TP2, 48 weeks). Median PFS was calculated based on time averaged dose (cumulative dose in a time interval divided by the planned number of dosing days) of PAN received to determine the potential role of dose adjustments/interruptions on efficacy. PFS was analyzed by Kaplan-Meier estimates. A safety analysis was conducted of AEs for TP1/TP2 for pts who completed TP2. Due to interdependencies among outcomes, further investigations of these data are needed. Results: Among the pts enrolled in the PAN-BTZ-Dex arm (N = 387), 169 (44%) completed TP1 and 102 (26.4%) completed TP2. Overall, pts who received a longer duration of treatment with PAN-BTZ-Dex demonstrated a longer PFS (Figure). Median PFS for pts who received PAN-BTZ-Dex and completed TP1 was 14.65 months (95% CI, 12.94, 16.85) and 17.64 months (95% CI, 15.90, 20.07) for those who completed TP2. In addition, nCR/CR rate was 52.9% for pts who completed TP2. Overall, the rates of commonly observed grade 3/4 AEs (≥ 20%) in the PAN-BTZ-Dex arm were thrombocytopenia (TCP, 57.0%), diarrhea (25.5%), and asthenia/fatigue (23.9%). Safety analysis for pts who completed TP2 demonstrated the higher rate of AEs in TP1 vs TP2 (excluding AEs that continued from TP1). For pts in the PAN-BTZ-Dex arm who completed treatment (n = 102), the rates of grade 3/4 events in TP1 and TP2 for common AEs were TCP (47.1% and 5.9%), diarrhea (25.5% and 8.8%), and asthenia/fatigue (19.6% and 5.9%). For pts in the Pbo-BTZ-Dex arm who completed treatment (n = 102), the rates for TP1 and TP2 were TCP (10.8% and 1.0%), diarrhea (5.9% and 0%), and asthenia/fatigue (7.8% and 0%). About half the pts (218/387; 56.3%) in the PAN-BTZ-Dex arm did not enter TP2 (112/218; 51.4% discontinued to due AEs). Analysis of time averaged dose of safety set pts on the PAN-BTZ-Dex arm demonstrated a median PFS of 12.71 (95% CI, 10.58, 14.19) months for pts who received >15-20 mg of PAN and 10.90 months (95% CI, 8.08, 12.71) for >10-15 mg. Conclusions: These data highlight the PFS and nCR/CR rate among pts able to complete TP2 with PAN-BTZ-Dex. Furthermore, for pts who completed the entire treatment regimen, the incidence of new/worsening AEs in TP2 where BTZ was administered on a once weekly schedule was decreased. Pts who received a lower time averaged dose due to dose adjustments/interruption of PAN had a similar median PFS to pts who received a time averaged dose closer to the planned dose. Together, these data support the hypothesis that optimal management of AEs for pts receiving PAN-BTZ-Dex via dose adjustments including BTZ and/or concomitant medications, particularly earlier during their course of therapy, could increase treatment duration and maintain outcomes. Figure 1 Figure 1. Disclosures San Miguel: Millennium: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Onyx: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; MSD: Membership on an entity's Board of Directors or advisory committees. Jedrzejczak:Amgen, Novartis : Consultancy, Research Funding. Guenther:Novartis: Consultancy, Research Funding. Siritanaratkul:Novartis: Research Funding; Roche: Research Funding; Janssen: Research Funding. Schlossman:Millennium: Consultancy. Hou:Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene Corporation: Honoraria, Membership on an entity's Board of Directors or advisory committees. Lonial:Millennium: Consultancy; Celgene: Consultancy; Novartis: Consultancy; BMS: Consultancy; Onyx: Consultancy; Sanofi: Consultancy. Sopala:Novartis Pharma AG: Employment. Redhu:Novartis : Employment. Paul:Novartis: Employment. Corrado:Novartis Pharma AG: Employment. Binlich:Novartis Pharma SAS: Employment. Richardson:Takeda: Research Funding; Millennium: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees.

Styles APA, Harvard, Vancouver, ISO, etc.

13

Sweat, Dan E., et Jacquelyn A. Anthony. « The role of corporations in urban revitalization. The experience of the atlanta project ». National Civic Review 84, n^o 3 (1995) : 239–47. http://dx.doi.org/10.1002/ncr.4100840309.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

14

Novakovich Gübelin, Marjorie, et Luis Mauricio Peralta Herrera. « Estado Actual de los Gobiernos Corporativos después de la Primera Aplicación de la Norma de Carácter General N° 341 de la SVS ». Revista summa de arithmetica, n^o 4 (31 décembre 2014) : 41–54. http://dx.doi.org/10.11565/sda.v1i4.39.

Texte intégral

Résumé :

El Gobierno Corporativo (GC) es el conjunto de instancias y prácticas de la empresa en el proceso de toma de decisiones que contribuyen a la creación de valor a lo largo del tiempo, en un marco de transparencia y responsabilidad organizacional hacia las partes interesadas de la Empresa. Un buen GC debe incorporar y desarrollar permanentemente prácticas de incentivos y respeto a los derechos de los accionistas y a los grupos de interés que participan directa o indirectamente en la Empresa, a objeto de obtener beneficios conjuntos de ésta. La presencia de numerosos grupos económicos en Chile, de origen nacional y extranjeros, sumada a la alta concentración de propiedad de éstos, generó que los organismos fiscalizadores nacionales, como lo es la SVS, emitiera la Norma de Carácter General (NCG) N°341. Ello en consideración a la importancia que reviste para el mercado de valores que las sociedades anónimas abiertas revelen sus políticas y prácticas de gobiernos corporativos, de forma que los inversionistas tengan suficiente información respecto a ello.

Styles APA, Harvard, Vancouver, ISO, etc.

15

Isaacs, Tracy. « Corporate Agency and Corporate Wrongdoing ». New Criminal Law Review 16, n^o 2 (2013) : 241–60. http://dx.doi.org/10.1525/nclr.2013.16.2.241.

Texte intégral

Résumé :

This article presents a philosophical defense of the view that corporations are legitimate responsible agents who may be considered criminally liable under the law. When corporations engage in blameworthy, irresponsible, or criminal actions, corporations are responsible for their actions. Whether this means we should think of them as persons in any robust sense is a separate question and we should be skeptical about conflating responsible agency with personhood. The article concludes with the claim that responsible agency and personhood are conceptually distinct, and that in the end responsible agency is a sufficient basis for criminal liability.

Styles APA, Harvard, Vancouver, ISO, etc.

16

Bauer, John. « Chief elements of controversy in public utility rate making III. Depreciation practice among large industrial corporations ». National Municipal Review 14, n^o 8 (5 janvier 2007) : 506–11. http://dx.doi.org/10.1002/ncr.4110140809.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

17

Schram, Ashley, et Sharni Goldman. « Paradigm Shift : New Ideas for a Structural Approach to NCD Prevention Comment on "How Neoliberalism Is Shaping the Supply of Unhealthy Commodities and What This Means for NCD Prevention" ». International Journal of Health Policy and Management 9, n^o 3 (9 novembre 2019) : 124–27. http://dx.doi.org/10.15171/ijhpm.2019.105.

Texte intégral

Résumé :

It is a well-documented fact that transnational corporations engaged in the production and distribution of health-harmful commodities have been able to steer policy approaches to address the associated burden of non-communicable diseases (NCDs). While the political influence that corporations wield stems in part from significant financial resources, it has also been enabled and magnified by what has been referred to as global health’s neoliberal deep core, which has subjected health policy to the individualisation of risk and responsibility and the privileging of market-based policy responses. The accompanying perspective article from Lencucha and Thow draws attention to neoliberalism in the NCD space and the way it has historically structured patterns of thinking and doing that foreground economic interests over health considerations. In this commentary, we explore how shifting from a focus on material power to discursive power creates space to see the NCD agenda as a battle of economic ideas as well as dollars, and consequently the importance of public health engagement in the next vision for the economy.

Styles APA, Harvard, Vancouver, ISO, etc.

18

Berdeja, Jesus G., Tara K. Gregory, Suman Kambhampati, Bertrand M. Anz, Stefano R. Tarantolo, Anthony A. Meluch et Jeffrey V. Matous. « A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM) ». Blood 134, Supplement_1 (13 novembre 2019) : 603. http://dx.doi.org/10.1182/blood-2019-130277.

Texte intégral

Résumé :

Background: The introduction of novel agents such as proteasome inhibitors (PI) and immunomodulatory drugs (IMiDs) with and without corticosteroids has revolutionized treatment (tx) and improved survival rates for MM. IMID/PI triplets such as VRD (bortezomib, lenalidomide, dexamethasone), VTD (bortezomib, thalidomide, dexamethasone), or KRD (carfilzomib, lenalidomide, dexamethasone) are preferred inductions for transplant-eligible patients (pts). Unfortunately, the PI often has unique safety events such as peripheral neuropathy (PN) or cardiac issues that can impact the quality of life. Elotuzumab is a mAb with a dual mechanism of action (tagging MM cells and activating NK cells by binding SLAMF7). The combination of elotuzumab, lenalidomide, and dexamethasone (ERd), is active, well-tolerated, and approved by the FDA for pts with relapsed MM. In this study, we will determine the feasibility of incorporating ERd into a transplant-eligible pt population. Methods: Pts with newly diagnosed MM requiring chemotherapy planning to undergo autologous stem cell transplantation (ASCT) were enrolled. Induction of elotuzumab at 10 mg/kg was administered IV on days (D) 1, 8, 15, 22 of the 1st 2 28-day cycles and days 1, 15 of the third and fourth 28-day cycles. Lenalidomide was dosed at 25 mg orally on D 1-21 of each 28 day induction cycle. Dexamethasone was administered IV concurrent with elotuzumab (28mg orally 3-24 hours prior to infusion and 8 mg IV with elotuzumab), with 40 mg orally administered on D 8 and 22 of cycles 3 and 4. After completion of the 4 induction cycles, pts proceeded to mobilization and ASCT though pts who refused transplantation were allowed to proceed directly to consolidation and maintenance if the investigator believed the pt was deriving benefit. 70-120 days after ASCT, 4 cycles of consolidation were administered (dosing similar to cycles 3-4 of induction but with lenalidomide at 15mg). Pts then went on to maintenance with elotuzumab 20 mg/kg IV on D 1, oral lenalidomide 10mg +/- 5 mg D 1-21 and dexamethasone 28mg oral/8 mg IV prior to elotuzumab infusion were dosed in 28-day cycles for up to 24 months. The primary endpoint was the induction feasibility rate (IFR) defined as the percentage of pts successfully completing 4 cycles of induction tx with ERd and able to start ASCT. Secondary end points were complete response rate (≥nCR), overall response rate (≥PR), progression-free survival (PFS) and overall survival (OS). AEs were assessed according to CTCAE V4 and responses were assessed using the revised IMWG criteria. Results: 52 pts were enrolled: 56% male, median age 61 ys, 12% RISS III, 21% high-risk cytogenetics [17p del, t(4;14), and/or t(14;16)]. To date, 26 (50%) pts remain on active tx. 4 pts refused transplantation despite being eligible and were excluded from the IFR calculation. The IFR was 69% and the best overall response rate (ORR) was 92% (69% ≥ VGPR). With a median follow up of 20 mos, median PFS and OS for all pts were not reached. The 18 mo PFS and OS were 83% and 89% respectively. The most common AEs were fatigue (59.6%), diarrhea (42.3%) and nausea (42.3%). PN was seen in 29%, and all events were ≤ G2. There were 28 SAEs in 20 pts, including 12 tx-related SAEs. There was 1 tx-related death due to heart failure in a pt with no history of prior cardiac issues who had subsequent therapy. 29% of pts met the high-risk (HR) criteria (defined as RISS III or high risk cytogenetics) and 29% of pts were considered standard-risk (RISS I and no high-risk cytogenetics). The best ORR was 87% (67% ≥ VGPR) for HR pts and 93% (53% ≥ VGPR) for SR pts and the IFR was 57% for HR pts and 64% for SR pts. The median PFS and OS were 20.5 mos and 22.0 mos respectively for HR pts and have not been reached for SR pts. Conclusions: ERd induction, consolidation and maintenance was feasible and well tolerated in conjunction with ASCT in transplant-eligible pts. Despite high ORR for all pts, HR patients had inferior PFS and OS. This study supports the continued evaluation of this regimen in SR pts. Disclosures Berdeja: Amgen Inc, BioClinica, Celgene Corporation, CRISPR Therapeutics, Bristol-Myers Squibb Company, Janssen Biotech Inc, Karyopharm Therapeutics, Kite Pharma Inc, Prothena, Servier, Takeda Oncology: Consultancy; Poseida: Research Funding; AbbVie Inc, Amgen Inc, Acetylon Pharmaceuticals Inc, Bluebird Bio, Bristol-Myers Squibb Company, Celgene Corporation, Constellation Pharma, Curis Inc, Genentech, Glenmark Pharmaceuticals, Janssen Biotech Inc, Kesios Therapeutics, Lilly, Novartis, Poseida: Research Funding. Gregory:Takeda: Speakers Bureau; Celgene: Speakers Bureau; Poseida: Research Funding; Amgen: Speakers Bureau. OffLabel Disclosure: Yes, this was an investigational clinical study of the combination of elotuzumab, lenalidomide, and dexamethasone in the induction, consolidation, and maintenance treatment of transplant-eligible patients newly diagnosed with multiple myeloma.

Styles APA, Harvard, Vancouver, ISO, etc.

19

Dan-Cohen, Meir. « Epilogue on “Corporate Personhood” and Humanity ». New Criminal Law Review 16, n^o 2 (2013) : 300–308. http://dx.doi.org/10.1525/nclr.2013.16.2.300.

Texte intégral

Résumé :

In discussions of corporate criminal liability, the question of corporations’ moral personhood often plays a central role. These concluding remarks point out some troubling repercussions of the notion of personhood on our conception of human beings and their moral status. Humanity rather than personhood is proposed as a more appropriate category for grounding humans’ dignity and their rights. This way of framing the discussion helps distinguish the proper treatment of humans from that of other subjects, be they corporations or animals.

Styles APA, Harvard, Vancouver, ISO, etc.

20

Ido, Kentaro, Hideo Koh, Hiroshi Okamura, Shiro Koh, Satoru Nanno, Mitsutaka Nishimoto, Asao Hirose et al. « Impact of Donor KIR and HLA Genotypes on Clinical Outcomes According to Pre-Transplant Remission Status after HLA-Haploidentical Transplantation with Post-Transplantation Cyclophosphamide ». Blood 134, Supplement_1 (13 novembre 2019) : 2030. http://dx.doi.org/10.1182/blood-2019-125173.

Texte intégral

Résumé :

INTRODUCTION HLA-haploidentical allogeneic hematopoietic cell transplantation (allo-HCT) using post-transplantation cyclophosphamide (PT/Cy-haplo) can be a standard of care in patients suffering from poor prognostic hematological malignancies without conventional donors. Regarding killer cell immunoglobulin-like receptor (KIR) and HLA information on optimal donor selection in PT/Cy-haplo settings, the following factors associated with improved survival have been reported: HLA-DR/HLA-DP mismatch, KIR receptor-ligand mismatch, KIR B/x haplotype with KIR2DS2, and inhibitory KIR gene mismatch (Willem 2019, Solomon 2018, Symons 2010). However, the results were still inconclusive. In addition, it remains unknown whether the graft-versus-leukemia/tumor (GVL) effect of donor KIRs or HLAs is modified by residual tumor burden at PT/Cy-haplo. METHODS We retrospectively examined consecutive patients who received PT/Cy-haplo at our institution between June 2009 and December 2018. In both patients and donors, 16 KIR genes were genotyped using KIR SSO Genotyping Test (One Lambda, Inc.) and HLA allele typing was performed at HLA-A, -B, -C, and -DRB1. Cumulative incidence of relapse (CIR) was estimated using a cumulative incidence curve with nonrelapse mortality as a competing risk and compared using the Gray's test. RESULTS A total of 91 patients with available KIR typing data were eligible. Of these, HLA typing data were unavailable for 5 patients (5.5%). In this cohort, 76 HLA-C mismatched transplants (88%) were included, and the frequencies of donor KIR ligand were 78 (90.7%) in C1/C1, 8 (9.3%) in C1/C2, and 0 in C2/C2. The median age was 48 years (range, 17 - 68 years). Median follow-up time among survivors was 1,271 days (range, 242 - 3,135 days) after PT/Cy-haplo. This study included 54 AML, 6 MDS, 2 CML, 13 ALL, and 16 NHL patients. Thirty-four patients (37%) showed complete remission (CR) at PT/Cy-haplo, and 37 on the secondor third transplant (40.7%). In CR population at PT/Cy-haplo, the patients who underwent PT/Cy-haplo from a KIR2DS1-positive donor had significantly lower rates of CIR than those from a KIR2DS1-negative donor (2-year CIR, 9.2% vs 42%; P = 0.037; Figure 1A). Due to unavailability of cases, we were unable to perform the subgroup analysis based on donor C1 or C2 status. In PT/Cy-haplo from a KIR3DS1- or KIR2DL5-positive donor, similar results were obtained, most likely due to genetic linkage disequilibrium among these genes. No other donor KIR genes were associated with CIR. Furthermore, PT/Cy-haplo from a KIR2DS1-positive donor was significantly associated with improved OS (2-year OS, 83% vs 34%; P = 0.01; Figure 1C). Also, PT/Cy-haplo from a B/x donor significantly increased OS (2-year OS, 77% vs 35%; P = 0.019), but did not decrease CIR (2-year CIR, 16% vs 40%; P = 0.122). These results suggested that donor KIR2DS1 could have a more crucial role in prevention of leukemia relapse than donor B/x haplotype. In non-complete remission (NCR) population at PT/Cy-haplo, however, PT/Cy-haplo from a KIR2DS1-positive donor and a B/x donor did not significantly improve CIR (Figure 1B) or OS (Figure 1D). Although we investigated the following previously reported models: KIR mismatch with ligand incompatibility model, receptor-ligand model, missing ligand model, inhibitory KIR gene model, and HLA-DRB1 disparity of graft-versus-host direction, none was found to be associated with significantly improved CIR or OS. CONCLUSION We found that in PT/Cy-haplo settings, with donor-recipient HLA-C mismatch in almost all cases, a KIR2DS1-positive donor significantly contributed to decreased CIR and increased OS in CR population at PT/Cy-haplo, but not in NCR population. These results were consistent with the 2012 NEJM data by Venstrom et al in patients undergoing allo-HCT from HLA-matched or one-allele mismatched unrelated donors. Although the exact mechanism remains unclear, activating KIR2DS1, known as a player in the activation and tolerance of NK cells, could mediate NK-cell function and enhance GVL effect through NK alloreactivity in low tumor burden status at PT/Cy-haplo also in the PT/Cy-haplo setting. Our results may contribute to the establishment of an optimal donor selection algorithm. In future, elucidating the detailed mechanism of our findings could lead to the development of a novel preventive or therapeutic strategy for leukemia relapse. Disclosures Ido: MSD K.K.: Honoraria. Koh:Alexion: Honoraria; DAIICHI SANKYO COMPANY: Honoraria; MSD K.K: Honoraria; Takeda Pharmaceutical: Honoraria, Research Funding; NIHON PHARMACEUTICAL: Honoraria; Takeda Science Foundation: Research Funding; Chugai Pharmaceutical: Research Funding; Amgen Astellas BioPharma: Research Funding; Asahi Kasei Corporation: Research Funding; IQVIA Services Japan: Research Funding. Okamura:MSD K.K: Honoraria; Eisai Co., Ltd: Honoraria. Koh:Bristol-Myers Squibb: Honoraria. Nanno:Eisai Co., Ltd.: Honoraria; MSD K.K: Honoraria; Chugai Pharmaceutical Co., Ltd.: Honoraria. Nakamae:Novartis: Honoraria, Research Funding; Takeda Pharmaceutical Co., Ltd.: Honoraria; Japan Blood Products Organization: Honoraria; Kyowa-Hakko Kirin Co.,Ltd: Honoraria; Astellas Pharma Inc.: Research Funding; Bristol-Myers Squibb: Honoraria; Pfizer Japan Inc.: Honoraria, Membership on an entity's Board of Directors or advisory committees; Chugai Pharmaceutical Co., Ltd.: Honoraria, Membership on an entity's Board of Directors or advisory committees; Alexion: Honoraria; Celgene: Honoraria; Janssen: Honoraria; Nippon Shinyaku: Honoraria; Otsuka Pharmaceutical: Honoraria, Membership on an entity's Board of Directors or advisory committees; Shire Japan KK.: Honoraria. Nakashima:Novartis: Honoraria; Kyowa-Hakko Kirin Co.,Ltd: Honoraria; Eisai Co.,Ltd: Honoraria, Research Funding; Celgene Corporation: Research Funding; Bristol-Myers Squibb: Honoraria; Astellas Pharma Inc.: Research Funding; Amgen Astellas BioPharma K.K.: Honoraria, Research Funding; AbbVie Inc.: Research Funding. Nakane:Kyowa-Hakko Kirin Co.,Ltd: Honoraria; Chugai Pharmaceutical Co., Ltd.: Honoraria; DAIICHI SANKYO COMPANY, LIMITED.,: Honoraria; Mundipharma K.K.: Honoraria; Novartis: Honoraria; Janssen Pharmaceutical K.K.: Research Funding; MSD K. K,: Research Funding; Pfizer Japan Inc.: Research Funding; Bayer Yakuhin, Ltd: Research Funding. Hino:Taiho Pharama: Research Funding; Takeda Pharmaceutical Co., Ltd: Honoraria, Research Funding; Astellas Amgen BioPharma: Honoraria; Bristol-Myers Squibb: Honoraria; Celgene: Honoraria; Chugai Pharmaceutical Co., Ltd: Honoraria, Research Funding; Daichi-Sankyo: Honoraria, Research Funding; Eisai: Research Funding; Janssen: Honoraria; Japan Blood Products Organization: Honoraria, Research Funding; Kyowa-Hakko Kirin Co.,Ltd: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Consulting fee, Research Funding; Mochica Pharmaceutical Co., Ltd: Honoraria; Pfizer Japan Inc: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi: Honoraria; Shire Japan KK: Honoraria; Sumitomo Dainippon Parma: Honoraria, Research Funding; Ono Pharmaceutical: Honoraria, Other: Consulting fee, Research Funding; Otsuka Pharmaceutical: Honoraria, Research Funding; Nippon Shinyaku: Honoraria; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Teijin: Research Funding; Nihon Pharmaceutical Co., Ltd: Research Funding; Astellas Pharma Inc: Honoraria, Research Funding; MSD: Honoraria, Research Funding; Mundipharma: Honoraria; Abbott: Research Funding; Alexion: Honoraria. Nakamae:Pfizer Japan Inc.: Honoraria, Membership on an entity's Board of Directors or advisory committees; Otsuka Pharmaceutical: Honoraria, Speakers Bureau; Novartis: Honoraria, Research Funding; Nippon Shinyaku: Honoraria; Kwowa-Hakko kirin Co., Ltd.: Honoraria; Japan blood Products Organization: Honoraria; Janssen: Honoraria; Chugai Pharmaceutical Co., Ltd.: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria; Bristol-Myers Squibb: Honoraria; Astellas Pharma Inc.: Research Funding; Alexion: Honoraria; Takeda Pharmaceutical Co., Ltd.: Honoraria; Skire Japan KK.: Honoraria.

Styles APA, Harvard, Vancouver, ISO, etc.

21

Singh, Samrat, et Somroop Siddhanta. « A comparative study of Non-Colour Bank segment among leading paint brands in Asansol market ». Gyan Management Journal 18, n^o 1 (31 août 2023) : 21–29. http://dx.doi.org/10.48165/gmj.2023.18.1.3.

Texte intégral

Résumé :

The Indian paint industry is one of the fastest growing ones in the country, maintaining double digit growth rates over the last few years, primarily due to shift in consumption patterns of the decorative paints. However, the Non-Colour Bank (NCB) segment consisting of enamels, primers, thinners, are not showing similar growth patterns, and is dominated by one firm. This study investigates the Availability, On-time delivery, Incentive schemes, and Customer Service pattern of Non-Colour Bank (NCB) products of Asian Paints Ltd., the market leader, and Other Brands, primarily including Berger Paints Ltd. in the Asansol Municipal Corporation area. The results will help Berger Paints, the market follower, to be aware of its position in the market while also assist other firms in finding out the lacunae regarding various NCB products in Asansol area in order to compete and have a strategic edge over other paint brands in the survey area.

Styles APA, Harvard, Vancouver, ISO, etc.

22

J.L.H.R, Wijegunasakara. « Non Communicable Disease Programme of Colombo District, Sri Lanka : A Technical Report ». International Journal of Medical Science and Clinical Invention 7, n^o 12 (19 décembre 2020) : 5169–73. http://dx.doi.org/10.18535/ijmsci/v7i12.07.

Texte intégral

Résumé :

Non Communicable Diseases (NCD) are the dominant chronic health problem in Sri Lanka. NCDs are basically classified into 2 types; acute NCD & chronic NCD. Policies, Strategies, Activities and monitoring and evaluation plans are in place in the National NCD programme. The objective of this case study is to study the Non Communicable Disease Programme of the division of Regional Director of Health Services (RDHS) – Colombo. Key informant’s interviews, review of secondary literature and observation in district review meetings were used to collect information. It was found that RDHS division - Colombo is responsible for both preventive and curative heath care for a population of 2.2 Million through 56 health care institutions. With regard to NCDs; injury surveillance, advocacy, capacity building, development of information, education & communication material, social media strategies and regular reviews are in good progress while gaps were seen in pre admission care, coverage of service, utilization pattern, treatment of NCDs, health promotion, inter sectorial corporation and information management system. Nominal group technique was used for prioritization. The issue of “NCD curative care provision is not optimum” was selected as the highest priority problem. Fish born diagram was developed to find root causes. The arm of “Physician factors” was selected to give recommendations and action plan was prepared accordingly.

Styles APA, Harvard, Vancouver, ISO, etc.

23

Rosenblatt, Jacalyn, Irit Avivi, Noam Binyamini, Lynne Uhl, Poorvi Somaiya, Dina Stroopinsky, Kristen Anna Palmer et al. « Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and May Lead to Eradication of Measureable Disease ». Blood 126, n^o 23 (3 décembre 2015) : 4218. http://dx.doi.org/10.1182/blood.v126.23.4218.4218.

Texte intégral

Résumé :

Abstract Autologous stem cell transplantation (ASCT) for multiple myeloma (MM) offers a unique setting to incorporate immunotherapy in an effort to target residual disease. Our group has developed a cancer vaccine in which dendritic cells (DCs) are fused to autologous tumor cells resulting in the presentation of multiple tumor antigens with the capacity to elicit a broad anti-tumor response. A fundamental challenge to developing a more effective tumor vaccine is overcoming the immunosuppressive milieu by which tumor cells evade host immunity. Up-regulation of the PD-1/PDL1 pathway represents a key element contributing to tumor-mediated tolerance, and potentially muting response to vaccination. We are conducting a clinical trial in which patients with MM are treated with an anti-PD1 antibody (Pidilizumab, MDV9300) in combination with a dendritic cell/myeloma fusion cell vaccine following autologous transplantation. 22 patients have been treated with post-transplant immunotherapy. Mean age was 64. MM cells were isolated from bone marrow and were identified by expression of CD38 or CD138. Mean tumor cell yield was 118x106 cells. Adherent mononuclear cells were isolated from leukapheresis collections and cultured with GM-CSF and IL-4 for 5-7 days, then exposed to TNFα for 48-72 hours to generate mature DCs. DCs expressed co-stimulatory (mean CD86 75%) and maturation markers (mean CD83 50%). DC and MM cells were co-cultured with PEG and fusion cells were quantified by determining the percentage of cells that co-express unique DC and myeloma antigens. Mean fusion efficiency was 41% and the mean cell dose generated was 4 x 106 fusion cells. Mean viability of the DC, myeloma, and fusion preparations was 92%, 89%, and 85%, respectively. As a measure of their potency as antigen presenting cells, DC/MM fusions potently stimulate allogeneic T cell proliferation ex-vivo (Mean stimulation index of 1.9, 9.2 and 7.1 for tumor, DC and DC/myeloma fusions respectively, n=21) Post-transplant immunotherapy was initiated after recovery from transplant-related toxicities. Median time from transplant to initiation of post-transplant immunotherapy was 80 days. Patients received 3 doses of Pidilizumab at 6-week intervals. DC/myeloma fusion cells vaccination is administered 1 week before each dose of Pidilizumab. To date, 22 patients have completed vaccinations and Pidilizumab. Adverse events judged to be potentially treatment related included grade 1-2 diarrhea, arthralgias, myalgias, fatigue, headache, nausea, chills, transaminitis, cytopenia, elevated TSH, and vaccine site reactions. A significant increase in circulatingtumor reactive lymphocytes was noted following post-transplant immunotherapy, as determined by T cell expressionof IFN-γ by CD8 cells following ex-vivo co-culture withautologous myeloma cell lysate. Mean percentage of tumor reactiveCD8 cells increased from 1.8% post-transplant to a peak of 9.16% following immunotherapy. In the post-transplant period, regulatory T cells fell to minimal levels and remained low throughout the period of immunotherapy. 6 patients achieved a best response of VGPR, 6 patients have achieved a nCR/CR, including 3 who converted to CR following immunotherapy. Median PFS from transplant is 19 months with ongoing follow up. In summary, DC/MM fusion cell vaccination in conjunction with PD1 blockade following ASCT was well tolerated, potently induced anti-tumor immunity, and in a subset of patients, resulted in the eradication of post-transplant measurable disease. Disclosures Richardson: Gentium S.p.A.: Membership on an entity's Board of Directors or advisory committees, Research Funding; Jazz Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Research Funding; Millennium Takeda: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Celgene Corporation: Membership on an entity's Board of Directors or advisory committees. Laubach:Novartis: Research Funding; Onyx: Research Funding; Celgene: Research Funding; Millennium: Research Funding. Anderson:Celgene: Consultancy; Millennium: Consultancy; BMS: Consultancy; Gilead: Consultancy; Oncopep: Equity Ownership; Acetylon: Equity Ownership. Rowe:BioSight Ltd.: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy; BioLineRx Ltd.: Consultancy. Kufe:Genus Oncology: Consultancy, Equity Ownership.

Styles APA, Harvard, Vancouver, ISO, etc.

24

Adachi, Sho Hei, Li Min Bao et Osamu Yamazaki. « Structural Analysis of a Teat Cup Liner ». Applied Mechanics and Materials 43 (décembre 2010) : 675–77. http://dx.doi.org/10.4028/www.scientific.net/amm.43.675.

Texte intégral

Résumé :

This study attempts to analyze the structure of the thin-walled part in the teat cup liner for FEM by the finite-element method (FEM) and to determine the most suitable structure for it. For the first step, we prepared a specimen liner made from NBR (Acrylonitrile-Butadiene Rubber) and silicon rubber (made by ORION MACHINERY CO., LTD.) and conducted tensile and compression tests for mechanical scraping properties of rubber Data. We then analyzed the thin-walled part using SolidWorks Simulation (SolidWorks Corporation) for finite-element analysis in liner process from expression of milk into nipple massage.

Styles APA, Harvard, Vancouver, ISO, etc.

25

Lauber, Kathrin, Harry Rutter et Anna B. Gilmore. « Big food and the World Health Organization : a qualitative study of industry attempts to influence global-level non-communicable disease policy ». BMJ Global Health 6, n^o 6 (juin 2021) : e005216. http://dx.doi.org/10.1136/bmjgh-2021-005216.

Texte intégral

Résumé :

IntroductionThere is an urgent need for effective action to address the over 10 million annual deaths attributable to unhealthy diets. Food industry interference with policies aimed at reducing non-communicable diseases (NCDs) is widely documented at the national level but remains under-researched at the global level. Thus, this study explores how ultra-processed food industry actors have attempted to influence NCD policy at WHO.MethodsA combination of inductive and deductive thematic coding of internal industry documents, academic literature and interviews with key informants from international organisations and global civil society was used to identify action-based strategies ultra-processed food industry actors employ to influence global-level policy.ResultsUltra-processed food industry actors have attempted to influence WHO and its policies through three main action-based strategies: coalition management, involvement in policy formulation, and information management. Coalition management includes the creation and use of overt alliances between corporations—business associations—and more covert science-focused and policy-focused intermediaries, the hiring of former WHO staff and attempted co-option of civil society organisations. Industry involvement in policy formulation is operationalised largely through the lobbying of Member States to support industry positions, and business associations gaining access to WHO through formal consultations and hearings. Information management involves funding and disseminating research favourable to commercial interests, and challenging unfavourable evidence.ConclusionWe provide novel insights into how ultra-processed food industry actors shape global-level NCD policy and identify a clear need to guard against commercial interference to advance NCD policy. In their approach, the political behaviour of multinational food corporations bears similarities to that of the tobacco industry. Increased awareness of, and safeguarding against, commercial interference at the national as well as the global level have the potential to strengthen the crucial work of WHO.

Styles APA, Harvard, Vancouver, ISO, etc.

26

Ramón Llulluy, Miguel, José Vilcapoma Chambergo et Ja Jorge Ime Valdez. « Identidad corporativa y resistencia al cambio del personal administrativo del edificio de Administración y Gobierno de la UNCP 2014 ». Prospectiva Universitaria 11, n^o 1 (8 août 2020) : 106–14. http://dx.doi.org/10.26490/uncp.prospectivauniversitaria.2014.11.12.

Texte intégral

Résumé :

El estudio correlacional tiene el propósito de caracterizar la identidad corporativa y resis-tencia al cambio organizacional y determi-nar la existencia de correlación entre estas variables en el personal administrativo del edifico de Administración y Gobierno de la Universidad Nacional del Centro del Perú. A una muestra de 30 trabajadores administra-tivos se les aplicó el instrumento de identidad corporativa y un cuestionario de resistencia al cambio; como la muestra es pequeña (n= 30, n < de 50) y es de tipo ordinal por lo que la contrastación de hipótesis se realizó con la t de student y para la significación del coefi-ciente de correlación la r de pearson al 95% de confianza estadística, la investigación ha concluido en lo siguiente: El personal admi-nistrativo del edificio y Administración de Go-bierno, posee una identidad media, también el personal administrativo tiene una resisten-cia al cambio media y existe relación inversa significativa entre identidad corporativa y re-sistencia al cambio de acuerdo a correlación de r pearson de (-0,4503) lo que revela que a menor identidad corporativa presenta mayor resistencia al cambio organizacional.

Styles APA, Harvard, Vancouver, ISO, etc.

27

Hong, Sungpyo, et Hanryeo Lim. « A Study of The Effect of the National Competency Standards(NCS) Recruitment System on the Human Resource Management in Corporations ». Journal of Skills and Qualifications 9, n^o 2 (30 juin 2020) : 107–27. http://dx.doi.org/10.35125/jsq.2020.9.2.107.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

28

Rosini, Alessandro Marco, et Rolf Henrique Neubarth. « Governança corporativa e a gestão de continuidade de negócios ». Revista Fatec Zona Sul 9, n^o 5 (23 juin 2023) : 1–23. http://dx.doi.org/10.26853/refas_issn-2359-182x_v09n05_02.

Texte intégral

Résumé :

As instituições do sistema financeiro brasileiro são pressionadas, por parte dos investidores, a aumentarem a eficiência operacional. Essas instituições tornam-se dependentes de plataformas tecnológicas, que precisam estar disponíveis, pois o risco operacional decorrente de indisponibilidades potencializa perdas financeiras significativas. A criação de uma gestão de continuidade de negócios eficaz permite a execução de um plano de resposta a eventos de alto impacto, indicando métodos, métricas e ferramentas para momentos de crise. Assim, este estudo tem como objetivo analisar a capacidade das empresas do setor financeiro para responderem a eventos de crises e de total parada em suas operações, atendendo aos requisitos específicos da NBR ISO/IEC 22301. Neste estudo de casos múltiplos, propomos uma coleta de informações, com entrevistas semiestruturadas, junto a uma amostra de cinco instituições do segmento financeiro, localizadas em Brasília e São Paulo e que aplicam frameworks de boas práticas de gestão de negócios e governança corporativa.

Styles APA, Harvard, Vancouver, ISO, etc.

29

Sunita et Shital Jhunjhunwala. « Women on Boards Scale : Cordons and Catalysts to Enter Boardroom ». Indian Journal of Corporate Governance 16, n^o 2 (décembre 2023) : 177–99. http://dx.doi.org/10.1177/09746862231205647.

Texte intégral

Résumé :

The underrepresentation of women on corporate boards and its influencers is an under-researched area in Asia, with the absence of standard scales measuring the catalysts and cordons for women’s career progression to boards. The research paper aims to develop and validate a multidimensional scale to measure the influences impacting women’s representation on boards in the Indian context. A pool of items was generated after a thorough review of existing literature and discussion with the experts. The Women on Boards Scale (WOBS) was constructed and validated based on a quantitative study of 509 female and male employees working in companies in Delhi and NCR. Exploratory factor analysis and confirmatory factor analysis techniques were applied for the study. The study confirms the structure of major barriers as individual, societal, and organisational barriers, along with the entry barriers that women face during entry or re-entry into the organization and enablers as well for women to reach boards. A comprehensive scale was constructed with significant psychometric properties to measure the barriers and enablers for women to reach boards. The scale provides a robust and useful tool for policymakers and corporations to improve gender diversity on corporate boards.

Styles APA, Harvard, Vancouver, ISO, etc.

30

Vogl, Dan T., Edward A. Stadtmauer, James Bradner, Lisa Davis, Thomas M. Paul, Emma C. Scott, Charles W. Nichols et al. « Combined Autophagy and Proteasome Inhibition for Multiple Myeloma : Final Results of a Phase 1 Trial of Hydroxychloroquine and Standard Dose Bortezomib for Patients with Relapsed or Refractory Myeloma ». Blood 118, n^o 21 (18 novembre 2011) : 1869. http://dx.doi.org/10.1182/blood.v118.21.1869.1869.

Texte intégral

Résumé :

Abstract Abstract 1869 BACKGROUND: The aggresome/autophagy pathway is the primary mechanism for disposal of ubiquitinated proteins for cells exposed to proteasome inhibition. Preclinical evidence shows that combining inhibition of the proteasome with bortezomib (Bz) and inhibition of autophagy with the anti-malarial drug hydroxychloroquine (HCQ) leads to enhanced cytotoxicity in myeloma cells. METHODS: Patients with relapsed or refractory myeloma enrolled on a standard 3+3 dose escalation design. Patients received 2-weeks of single-agent oral HCQ, followed by the addition of Bz on days 1, 4, 8, and 11 of 21-day cycles. HCQ and Bz doses were determined by dose level: (1) 200 mg qod / 1.0 mg/m2, (2) 200 qod / 1.3, (3) 200 qd / 1.3, (4) 200 bid / 1.3, (5) 400 bid / 1.3, (6) 600 bid / 1.3. Dose-limiting toxicity (DLT) was defined as grade ≥3 toxicity probably related to study therapy and occurring during the first 5 weeks, with the exception of any anemia or lymphopenia, neutropenia responsive to growth factor, platelets >10,000/mm3 not associated with bleeding, or gastrointestinal complaints relieved by symptomatic therapy. We used electron microscopy to characterize changes in autophagic vesicles in serial samples of peripheral blood mononuclear cells and CD138-selected bone marrow plasma cells. RESULTS: We enrolled 25 patients between 1/2008 and 2/2011, of which 21 patients completed at least 1 cycle of combined therapy and were evaluable for toxicity. The median duration of study participation was 14 weeks (range 1–77). Reasons for study discontinuation were side effects of therapy (6), lack of response (7), disease progression (11), and non-compliance (1). No protocol-defined dose limiting toxicities occurred, and the maximum tolerated dose was determined to be the top dose level of Bz 1.3 mg/m2 and HCQ 600 mg twice daily. Hematologic abnormalities were generally more attributable to disease progression than to treatment toxicity, but at the top dose level one patient had grade 3 thrombocytopenia and neutropenia after starting with a normal platelet count and ANC, without evidence of progression through therapy. At the top dose level, gastrointestinal toxicities predominated, including 5 out of 6 evaluable patients with some form of grade 3 GI toxicity. Treatment emergent neuropathy occurred in 7 patients but was restricted to grade 1 or 2 and was easily managed with dose reduction of the Velcade. Three patients came off study before receiving the combined regimen and were not evaluable for response. The best responses for the remaining 22 patients included 3 near complete responses (nCR), 3 minor responses (MR), 9 stable disease (SD), and 7 progression (PD). The 3 nCRs occurred in Bz-naïve patients receiving HCQ at 400 mg/d (1 pt) and 1200 mg/d (2 pts). Two patients who had previously progressed while receiving weekly maintenance Bz had MRs on study, including one who maintained a MR for over 7 months. Three additional Bz-refractory patients initially achieved stable disease during study treatment, with on study TTP of 8 weeks (at HCQ 1200 mg/d), 15 weeks (100 mg/d), and 17 weeks (200 mg/d). Preliminary analyses of vesicle counts at HCQ doses up to 800 mg/d identify individual patients with increases in autophagic vesicles in either peripheral blood or bone marrow plasma cells, but these are not consistent, nor is there any evident correlation with response. CONCLUSION: Combined Bz and HCQ is tolerable, with a phase 2 dose of Bz 1.3 mg/m2 and HCQ 1200 mg/d and likely hematologic and gastrointestinal DLTs. There is a suggestion of improved efficacy over Bz alone, with minor responses and long periods of stable disease in Bz-refractory patients. Final analysis of autophagy inhibition in correlative specimens, including the top dose cohort, will be available for the meeting. Disclosures: Vogl: Millennium Pharmaceuticals: Honoraria, Research Funding. Off Label Use: Hydroxychloroquine is FDA approved for treatment of malaria and rheumatoid arthritis. This paper discusses its use in treatment of myeloma. Carroll:Agios Pharmaceuticals: Research Funding; TetraLogic Pharmaceuticals: Research Funding; Sanofi Aventis Corporation: Research Funding; Glaxo Smith Kline, Inc.: Research Funding. Amaravadi:Millennium Pharmaceuticals: Honoraria, Research Funding.

Styles APA, Harvard, Vancouver, ISO, etc.

31

Rapoport, Aaron P., Edward A. Stadtmauer, Dan T. Vogl, Brendan M. Weiss, Gwendolyn K. Binder-Scholl, Dominic P. Smethurst, Jeffrey Finklestein et al. « Engineered T-Cells Expressing An HLA-Restricted Affinity-Enhanced TCR In Advanced Multiple Myeloma Patients Post Auto-SCT Engraft and Are Associated With Encouraging Post Auto-SCT Responses ». Blood 122, n^o 21 (15 novembre 2013) : 766. http://dx.doi.org/10.1182/blood.v122.21.766.766.

Texte intégral

Résumé :

Abstract Background Despite recent therapeutic advances, multiple myeloma (MM) remains primarily an incurable cancer. Patients experiencing rapid recovery of T cells post autologous stem cell transplant (auto-SCT) may have improved outcomes, and spontaneous cellular responses to tumor can occur, suggesting immune mediated control of tumor is possible. We and others have investigated therapeutic cancer vaccines that have shown promise in pilot studies, in particular following post-transplant infusion of activated autologous T cells. However, efficacy of these approaches may be limited by thymic selection which restricts the repertoire of T cell receptors (TCRs) to low affinity TCRs that cannot recognize the low level of antigen present on most tumor cells. We hypothesized that incorporation of affinity-enhanced tumor antigen-specific TCRs into autologous T cells infused post-transplant would overcome this limitation and improve response rates in the post auto-SCT setting. Methods We report interim results of a Phase II clinical trial (NCT01352286) to evaluate the safety and activity of autologous T cells genetically engineered to express an affinity-enhanced TCR that recognizes the NY-ESO-1/LAGE-1 peptide complex HLA‐A*0201‐SLLMWITQC; these cells are infused in the setting of profound lymphodepletion that accompanies high dose chemotherapy administered during auto-SCT. Patients with high risk or relapsed MM, who are HLA‐A*0201 positive, and whose tumor is positive for NY-ESO-1 and/or LAGE-1 by RT-PCR are eligible. CD25 depleted CD4 and CD8 T cells are activated and expanded using anti-CD3/CD28 antibody conjugated microbeads, and genetically modified with a lentiviral vector containing the TCR construct at a multiplicity of infection of 1. Engineered T cells are administered four days after high dose melphalan and two days following auto-SCT, at a dose range of 1-10 billion total cells with a minimum gene modification requirement of 10%. Patients are evaluated for MM responses in accordance with the IMWG criteria at 6 weeks, and 3 and 6 months post infusion. At 3 months, patients start lenalidomide maintenance. The initial 6 patient phase is complete and a 20 patient extension phase is ongoing. Results Prior to enrollment on study, patients had received a median of 3 prior therapies including 6 with prior transplant. 50% of tumors contained high risk chromosomal abnormalities, and NY-ESO-1 expression is correlated with adverse prognosis. 20 patients (average age of 57) have been infused with an average of 2.3 X 109 engineered T cells (range 4.5 X 108-3.9 X 109); this reflects an average clinical scale transduction efficiency of 34% (range 18% – 49%). Infusions have been well tolerated, and the majority of adverse events were related to the high dose melphalan. Possibly related SAEs were neutropenia and thrombocytopenia, and GI and metabolism disorders including diarrhea, colitis, hyponatremia and hypomagnesemia. 10, 4, 2, and 2 patients have reached the 1 year, 9 month, 6 month and 3 month assessment timepoints, respectively, and 17/20 patients are alive. Best response by day 100 is sCR/CR in 2/15 (13%), nCR in 10/15 (67%), and PR in 3/15% (20%), which compares favorably to historic responses in patients undergoing first or second transplant. Engineered T cells expanded and persisted in blood and marrow at 180 days by Q-PCR and flow-cytometry in all but one case (Figure). 7 patients progressed after day 100, which was accompanied either by loss of engineered T cells or loss of tumor antigen. Detailed phenotyping and functional analysis of engineered T cells, and correlates with clinical responses, is underway. Summary This is the first clinical evaluation of engineered T cells in the MM setting. Infusions are safe, well tolerated, and are associated with encouraging responses in a high risk myeloma population. A study evaluating the engineered T cells in a non-transplant study is underway. Disclosures: Stadtmauer: Celgene: Consultancy. Binder-Scholl:Adaptimmune: Employment. Smethurst:Adaptimmune: Employment. Brewer:Adaptimmune: Employment. Bennett:Adaptimmune: Employment. Gerry:Adaptimmune: Employment. Pumphrey:Adaptimmune: Employment. Tayton-Martin:Adaptimmune: Employment. Ribeiro:Adaptimmune: Employment. Levine:Novartis: cell and gene therapy IP, cell and gene therapy IP Patents & Royalties. Jakobsen:Adaptimmune: Employment. Kalos:Novartis corporation: CART19 technology, CART19 technology Patents & Royalties; Adaptive biotechnologies: Member scientific advisory board , Member scientific advisory board Other. June:Novartis: Patents & Royalties, Research Funding.

Styles APA, Harvard, Vancouver, ISO, etc.

32

Raschke, Verena, et Bobby Cheema. « Colonisation, the New World Order, and the eradication of traditional food habits in East Africa : historical perspective on the nutrition transition ». Public Health Nutrition 11, n^o 7 (juillet 2008) : 662–74. http://dx.doi.org/10.1017/s1368980007001140.

Texte intégral

Résumé :

AbstractObjectiveTo discuss factors which have underpinned the nutrition transition in the countries of East Africa, including Kenya, Uganda and Tanzania, from early colonisation to the current, oppressive political–economic structure.ResultsColonisation and neocolonisation in accordance with the desires of the New World Order have ensured the systematic extirpation of indigenous and traditional food habits in East Africa. These indigenous and traditional food habits, associated with myriad health benefits, have been progressively replaced by the globalised food system of the multinational corporations, a system inherently associated with the creation of non-communicable disease (NCD) epidemics throughout this region and globally. While the simplification of the East African food culture may be most apparent today, the nutrition transition has actually occurred over the past 400 years, since the onset of colonial occupation.ConclusionsIt is imperative that greater efforts be directed towards exposing the colonial and neocolonial forces which have undermined food security and health status in East Africa. Heightened awareness of these forces is essential for proposing genuine solutions to the nutrition transition and related NCD epidemics throughout this region and, indeed, worldwide.

Styles APA, Harvard, Vancouver, ISO, etc.

33

Žáček, Jiří, David Nečas et Michal Kubík. « Wear of Seal Materials in Magnetorheological Fluid : Effect of Seal Material Selection ». Materials Science Forum 1064 (17 juin 2022) : 71–78. http://dx.doi.org/10.4028/p-n4m48v.

Texte intégral

Résumé :

This paper is focused on magnetorheological (MR) dampers and their critical parts in terms of damper`s durability, which seems to be a piston-rod seal. An option to reduce the wear is to choose the proper material for that purpose. The wear measurements were conducted in an accelerated and simplified mode in a modified pin-on-flat (cylinder-on-flat) configuration, which was supposed to be more suitable for laboratory testing than original configurations. Suitable commercial materials for seals, like PTFE, NBR, SBR and polyurethanes, were tested and compared in commercial MR fluid MRF-132DG by LORD Corporation. It turned out that material H-PU95FDA had had the biggest wear resistance from all tested materials and therefore it was the most suitable material for durable seals, while PTFE seals are expected to be suitable in non-durable applications with low frictional forces.

Styles APA, Harvard, Vancouver, ISO, etc.

34

Mariath, Aline Brandão, et Ana Paula Bortoletto Martins. « ATIVIDADE POLÍTICA CORPORATIVA DA INDÚSTRIA DE ALIMENTOS E BEBIDAS ULTRAPROCESSADOS ». REI - REVISTA ESTUDOS INSTITUCIONAIS 8, n^o 2 (31 août 2022) : 303–20. http://dx.doi.org/10.21783/rei.v8i2.657.

Texte intégral

Résumé :

Não há dúvidas acerca do papel da indústria de alimentos e bebidas ultraprocessados na epidemia mundial de obesidade e doenças crônicas associadas à má-alimentação. As ações governamentais para regular as práticas desse setor industrial têm sido amplamente recomendadas para conter o avanço dessa pandemia. Contudo, a indústria de alimentos e bebidas ultraprocessados frequentemente atua para impedir regulações que impactem negativamente seus lucros. Neste artigo de revisão, apresentam-se a definição de atividade política corporativa, os métodos recomendados para identificar as estratégias e práticas empregadas pela indústria de alimentos e bebidas ultraprocessados, bem como o modelo proposto por pesquisadores da rede INFORMAS (International Network for Food and Obesity/NCD Research, Monitoring and Action Support) que é atualmente utilizado para classificar essas estratégias e práticas. Descrevemos estudos internacionais e nacionais nessa área, que demonstram que esse setor industrial utiliza estratégias e práticas bastante semelhantes àquelas da indústria do tabaco. Finalmente, destacamos a necessidade de se conduzir estudos que busquem determinar em que medida a interferência da indústria de alimentos e bebidas ultraprocessados de fato influencia o processo decisório e quais condições se associam ao seu sucesso.

Styles APA, Harvard, Vancouver, ISO, etc.

35

Ferreira, Camila dos Santos, et Mateus Cecílio Gerolamo. « Análise da relação entre normas de sistema de gestão (ISO 9001, ISO 14001, NBR 16001 e OHSAS 18001) e a sustentabilidade empresarial ». Gestão & ; Produção 23, n^o 4 (25 août 2016) : 689–703. http://dx.doi.org/10.1590/0104-530x2525-15.

Texte intégral

Résumé :

Resumo A sustentabilidade pode ser inserida no contexto empresarial como uma forma de minimizar impactos causados pelos processos produtivos. Organizações utilizam as normas dos sistemas de gestão para satisfazer os anseios das partes interessadas. Sendo assim, o objetivo do estudo foi analisar a relação entre normas de sistemas de gestão (ISO 14001, ISO 9001, OHSAS 18001 e NBR 16001) e a sustentabilidade empresarial. O objetivo foi alcançado seguindo as seguintes etapas: Primeiramente, os requisitos da sustentabilidade empresarial foram identificados, baseados em Índice de Sustentabilidade Empresarial, Indicadores Ethos e Global Reporting Initiative. Posteriormente, a matriz que relaciona os requisitos da sustentabilidade e os das normas foi construída. A matriz foi preenchida pela pesquisadora e por mais seis especialistas. As respostas foram consolidadas, gerando-se a Matriz de Relação Consolidada, a qual foi analisada e interpretada. As relações foram classificadas como forte, moderada, fraca ou nula. Os resultados da pesquisa apontam que ISO 9001 e OHSAS 18001 possuem relação fraca com a sustentabilidade empresarial. A ISO 14001 apresenta relação moderada e a NBR 16001, relação forte. A pesquisa concluiu que os padrões normativos podem auxiliar as empresas a introduzirem a sustentabilidade em seu contexto, no entanto, ISO 9001 e OHSAS 18001 são normas que abordam apenas alguns elementos da sustentabilidade empresarial. A NBR 16001 é a norma que mais apresenta elementos da sustentabilidade em seu escopo. Sendo assim, empresas que objetivam introduzir a sustentabilidade no ambiente corporativo poderiam focar na implementação da NBR 16001.

Styles APA, Harvard, Vancouver, ISO, etc.

36

Andritsos, Leslie, John C. Byrd, Jeffrey A. Jones, Becker Hewes, Thomas J. Kipps, Frank J. Hsu et Jan A. Burger. « Preliminary Results From A Phase I Dose Escalation Study to Determine the Maximum Tolerated Dose of Plerixafor In Combination with Rituximab In Patients with Relapsed Chronic Lymphocytic Leukemia ». Blood 116, n^o 21 (19 novembre 2010) : 2450. http://dx.doi.org/10.1182/blood.v116.21.2450.2450.

Texte intégral

Résumé :

Abstract Abstract 2450 Background: Dose intense rituximab in previously-treated patients (pts) with CLL has demonstrated modest activity. Preclinical data indicate that the CXCR4/CXCL12 axis plays a key role in CLL cell homing and retention in tissue microenvironments, such as the bone marrow. Disruption of this axis using the small-molecule CXCR4-antagonist, plerixafor, may abrogate stroma-mediated drug resistance, and enhance sensitivity of CLL cells to rituximab. To test this hypothesis, we initiated a phase 1 trial of plerixafor + rituximab in previously-treated pts with CLL. Aims: The primary objective was to determine the maximum tolerated dose (MTD) and safety of plerixafor when combined with rituximab. Methods: Adult pts with WBC≤ 50×109/L, intermediate/high risk CLL not refractory to rituximab, and with active disease by NCI criteria were eligible in this ongoing study. Pts were treated with 3x/week rituximab, as a 100mg flat dose on Day 1, and subsequently 375mg/m2 IV for 12 total doses (i.e. for 4 weeks). Plerixafor was given SC prior to rituximab starting at the 4th rituximab dose (Day 8) for 9 total doses. Cohorts of pts were treated at 1 of 4 dose levels with plerixafor (0.08mg/kg, 0.16mg/kg, 0.24mg/kg and 0.32mg/kg). Pts were observed for dose-limiting toxicities (DLT) from the first plerixafor dose (Day 8) through Day 29 and cohort advancement followed dose escalation rules using a 3+3 design. Peripheral blood (PB) CD34+ and CLL cells were enumerated on Days 8 and 26 by flow cytometry; PB samples were obtained at baseline pre-plerixafor treatment and at 2, 4, 6, 10, and 24 hours post-plerixafor. Responses were assessed as defined by Cheson et al (Blood, 1996). Results: 17 pts (median age 64 years; 88% male; Rai Stage IV: 53%) were enrolled, 3 pts each in the 0.08 and 0.24 mg/kg cohorts, 4 pts in the 0.16mg/kg cohort and 7 pts in the 0.32mg/kg cohort (Table 1). No DLTs were reported. Of 14 evaluable pts, 5 (36%) had partial response, 3 (21%) had stable disease for ≥2 months and 6 (43%) had progressive disease. Treatment-emergent, plerixafor-related adverse events (AEs) were seen in 5 pts and included diarrhea, vomiting, nausea, appetite loss, headache, hypoaesthesia and paraesthesia. All AEs were grade 1 except nausea (n=1) that was grade 2. Treatment-emergent serious AEs were seen in 2 pts (0.16mg/kg dose; grade 3 EBV infection, grade 2 gastrointestinal reflux disease and grade 2 dyspnea); all unrelated to plerixafor. On Day 8, there was a median 3.8-fold increase in PB CLL cells (range: 1.2 –15.0-fold), indicating CLL cell mobilization. On Day 26 fewer PB CLL cells were detected with a median fold increase of 1.5 (range, 0.9–8.0). Conclusions: The combination of plerixafor + rituximab in CLL pts with WBC < 50×109/L was well tolerated. CLL cells were mobilized following plerixafor, and partial remissions were seen in a proportion of pts. In some cases, maximum responses were seen several months after completion of rituximab, consistent with single agent therapy. This suggests that continued follow up may show additional responses in recently treated pts. Disclosures: Andritsos: Genzyme Corporation: Research Funding. Off Label Use: Plerixafor (Mozobil®), a hematopoietic stem cell mobilizer, is approved by the US FDA in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. Byrd: Genzyme Corporation: Research Funding. Jones: Genzyme Corporation: Research Funding. Hewes: Genzyme Corporation: Employment. Kipps: Genzyme Corporation: Research Funding. Hsu: Genzyme Corporation: Employment, Equity Ownership. Burger: Genzyme Corporation: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding.

Styles APA, Harvard, Vancouver, ISO, etc.

37

Maula, Tezar, et Goldie Gunadi. « SISTEM PAKAR DIAGNOSA KERUSAKAN MESIN ATM MENGGUNAKAN METODE CERTAINTY FACTOR PADA BANK UOB ». Infotech : Journal of Technology Information 10, n^o 1 (30 juin 2024) : 77–84. http://dx.doi.org/10.37365/jti.v10i1.250.

Texte intégral

Résumé :

Bank UOB (United Overseas Bank) Indonesia is a company operating in the banking industry. Some of the banking products provided by UOB include cards, savings, loans, investments and insurance. Apart from offering banking product services for individuals, UOB Indonesia also provides various banking products for corporations or business institutions. To provide the best service to its customers, currently UOB Indonesia has 142 ATMs spread throughout Indonesia. As business grows and the number of customers increases, transactions using ATMs increase rapidly. Disturbances and problems with ATM machines can result in a decrease in the level of customer satisfaction and loyalty towards UOB services. The solution to overcome this problem is to build a web-based expert system application that can be used to diagnose damage to NCR type ATM machines using the Certainty Factor method. In this research, application development was carried out using the PHP programming language and MySQL database. The benefit obtained from this application is that it makes it faster for UOB ATM technicians to determine damage to ATM machine equipment based on symptoms found during checking and then obtain the right repair solution. Because the application created is web-based so it can be accessed at any time from anywhere using a laptop or smartphone.ABSTRAKBank UOB (United Overseas Bank) Indonesia merupakan salah satu perusahaan yang bergerak di industri perbankan. Beberapa produk perbankan yang disediakan oleh UOB diantaranya adalah kartu, simpanan, pinjaman, investasi dan asuransi. Selain menawarkan layanan produk perbankan untuk perorangan UOB Indonesia juga menyediakan berbagai produk perbankan untuk korporasi atau institusi bisnis. Untuk memberikan pelayanan yang terbaik kepada para nasabahnya, saat ini UOB Indonesia memiliki 142 ATM yang tersebar di seluruh Indonesia. Seiring dengan pertumbuhan bisnis dan bertambahnya jumlah nasabah maka transaksi menggunakan ATM meningkat pesat. Gangguan dan kendala pada mesin ATM dapat mengakibatkan menurunnya tingkat kepuasan dan loyalitas nasabah terhadap pelayanan UOB. Solusi untuk mengatasi permasalahan tersebut adalah dengan membangun sebuah aplikasi sistem pakar berbasis web yang dapat dimanfaatkan untuk melakukan diagnosis kerusakan mesin ATM bertipe NCR menggunakan metode Certainty Factor. Dalam penelitian ini pengembangan aplikasi dilakukan dengan bahasa pemrograman PHP dan basis data MySQL. Manfaat yang diperoleh dari aplikasi ini adalah mempercepat teknisi ATM UOB menentukan kerusakan perangkat mesin ATM berdasarkan gejala yang ditemukan saat pengecekan dan kemudian memperoleh solusi perbaikan yang tepat. Karena aplikasi yang dibuat berbasis web sehingga dapat diakses setiap saat dari mana saja dengan menggunakan perangkat laptop maupun smartphone.

Styles APA, Harvard, Vancouver, ISO, etc.

38

Díez, Carlos Gómez-Jara. « Honest Services Fraud as a Criminal Breach of Fiduciary Duties ». New Criminal Law Review 18, n^o 1 (2015) : 100–128. http://dx.doi.org/10.1525/nclr.2015.18.1.100.

Texte intégral

Résumé :

From a comparative perspective, the challenges that American courts and legislators are facing when trying to construe an honest services fraud statute are familiar. Almost all European countries have a general provision that criminalizes any breach of fiduciary duties that brings about economic harm to the principal. The comparative inquiry also helps shed light on the way in which the offense should be defined in a future statute. First, honest services fraud should be treated as a separate offense that is different from fraud; more specifically, the offense of honest services fraud should be conceived as a midpoint between fraud and embezzlement. Second, this offense—which could be defined as a “disloyalty” or “mismanagement” crime—should be construed along the lines of a derivate action for breach of fiduciary duties, although with higher standards, given that its violation triggers criminal sanctions. Third, this new disloyalty offense should include elements that are not required by current law, including whether “actual” or “reasonably foreseeable harm” is caused and whether the breach of the fiduciary duty is the proximate cause of the actual harm. The time has come to create a freestanding general disloyalty offense that requires an actual or reasonably foreseeable harm to the corporation as a prerequisite to criminal liability.

Styles APA, Harvard, Vancouver, ISO, etc.

39

Joubert, Leonie Skene. « Hit Me(n) ». Matatu 54, n^o 1 (29 novembre 2023) : 124–33. http://dx.doi.org/10.1163/18757421-05401009.

Texte intégral

Résumé :

Abstract In the Global South, the adoption of the so-called Western diet in recent decades has resulted in a global pandemic of obesity and lifestyle-related diseases. However some academics argue that this diet should be reframed as the ‘neoliberal’ diet, one which is the outcome of a profit-driven industrial food system in which large multi-national corporations have disproportionate power to make, distribute, promote, and sell their products. Instead of framing lifestyle-related non-communicable diseases (NCD s) as the personal failure of the individual, this lens calls for a critique of a food system which shapes individual food and lifestyle choices. Yet social attitudes remain slow to respond to this shifting view of this pressing food-related NCD public health issue. Sugar is a key part of the formulation of many ultra-processed foods that are responsible for poor diet-related health outcomes. Hit Me(n) uses protest art as a communications tool to reframe the issue for the audience. It draws attention to the dopamine system in the brain by juxtaposing sugar alongside other addictive substances and behaviours that drive similar pleasure-seeking patterns. It further draws attention to the role that corporate and product branding plays in normalising and glorifying certain addiction-linked substances and behaviours. It questions who has the power to shape the system, and who does not.

Styles APA, Harvard, Vancouver, ISO, etc.

40

Benjamin, Heather L., James M. Rossetti, Aaron J. Lampkin, Christie Hilton, Entezam Sahovic, Haifaa Abdulhaq, Richard K. Shadduck, Namratha Vemulapalli, Amanda Hercules et John Lister. « Azacitidine in the Treatment of Elderly Patients with Acute Myelogenous Leukemia. » Blood 114, n^o 22 (20 novembre 2009) : 4164. http://dx.doi.org/10.1182/blood.v114.22.4164.4164.

Texte intégral

Résumé :

Abstract Abstract 4164 BACKGROUND Effective treatment of the elderly patient with acute myelogenous leukemia (AML) remains a challenging task. Elderly patients with AML usually respond poorly to standard induction chemotherapy. Response rates in elderly patients are in the range of 30–50% compared to 80–90% in younger patients. Moreover, prolonged hospitalization with treatment related mortality as high as 30% is typical in this older population. In a prior retrospective analysis done at our institution, azacitidine showed an overall response rate of 60% with limited toxicity when administered to patients older than 55 years of age with AML. We present an interim analysis of the first 13 patients enrolled in our prospective, phase II open label study using single agent azacitidine for elderly patients with AML. METHODS This is a prospective, phase II open label study using azacitidine in patients ≥ 60 years with AML. Inclusion criteria: Newly diagnosed AML (de novo or secondary, WHO criteria) and ECOG≤ 2. Promyelocytic (M3) phenotype was excluded. Patients with circulating blast count ≥ 30,000/mcl were treated with hydroxyurea until < 30,000/mcl. Azacitidine was given at a dose of 100 mg/m2 subcutaneously for 5 consecutive days every 28 days until disease progression or significant toxicity. G-CSF was given to patients with neutropenia (ANC < 1000/mcl) during all cycles excluding cycle one. RESULTS Thirteen patients have been enrolled to date. The mean age of patients is 75 years (range: 66–84). The mean baseline ECOG performance score was 1 with a mean during treatment of 1. Mean baseline bone marrow blast count was 57% (range: 21–100%). Overall response rate using the NCI response criteria (IWG criteria for patients with hematological improvement (HI) only) was 46% (6/13): complete response (CR; n=3; 23%), partial response (PR; n=1; 8%), and HI (n=2; 15%). One additional patient had a 94% reduction in marrow blasts, but failed to achieve transfusion independence. The mean number of days on treatment was 171+ (range: 13–606). The mean number of days hospitalized for diagnosis plus treatment or disease related complication was 21 (range: 7–72) with the majority of therapy being given in the outpatient setting. One patient required prolonged hospitalization after going on to allogeneic transplantation. The mean overall survival from diagnosis for all patients was 246+ days (range: 13–606). The mean overall survival for responders was 399+ days (range: 212–606). One patient continues on therapy with azacitidine at 606 days (CR). Of the other responders, one progressed at 420 days and is considering other options (CR), one died from an intra-cranial hemorrhage after receiving Mylotarg for disease progression at 454 days (CR), one progressed at 119 days and went on to another clinical trial (PR), and two died with disease at 212 and 347 days (HI). Non-hematological toxicity was limited to mild injection site skin reaction and fatigue in 77% (10/13) each. No treatment related deaths were observed. The dose and schedule of therapy remained constant in all but three patients: One patient required a 25% dose reduction after cycle 3 followed by another 25% reduction after cycle 11 due to drug induced marrow suppression, one patient required a 25% dose reduction after cycle 2 due to drug induced marrow suppression, and one patient required and tolerated a 25% dose escalation to recapture a CR after cycle 15. CONCLUSION This interim analysis suggests that the administration of subcutaneous azacitidine in an accelerated dosing schedule to elderly patients with acute myelogenous leukemia is a feasible and well-tolerated alternative to standard induction chemotherapy. Disclosures: Benjamin: Celgene Corporation: Research Funding. Off Label Use: Use of azacitidine in AML.. Rossetti:Celgene Corporation: Honoraria, Research Funding, Speakers Bureau. Sahovic:Celgene Corporation: Honoraria, Research Funding, Speakers Bureau. Abdulhaq:Celgene Corporation: Research Funding. Shadduck:Celgene Corporation: Honoraria, Research Funding, Speakers Bureau. Lister:Celgene Corporation: Research Funding.

Styles APA, Harvard, Vancouver, ISO, etc.

41

Sedláček, Jaroslav, et Veronika Popelková. « Non-financial information and their reporting—evidence of small and medium-sized enterprises and large corporations on the Czech capital market ». National Accounting Review 2, n^o 2 (2020) : 204–16. http://dx.doi.org/10.3934/nar.2020012.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

42

Li, Niu, Jian Wang, Susan S. Wallace, Jing Chen, Jia Zhou et Alan D. D’Andrea. « Cooperation of the NEIL3 and Fanconi anemia/BRCA pathways in interstrand crosslink repair ». Nucleic Acids Research 48, n^o 6 (25 janvier 2020) : 3014–28. http://dx.doi.org/10.1093/nar/gkaa038.

Texte intégral

Résumé :

Abstract The NEIL3 DNA glycosylase is a base excision repair enzyme that excises bulky base lesions from DNA. Although NEIL3 has been shown to unhook interstrand crosslinks (ICL) in Xenopus extracts, how NEIL3 participants in ICL repair in human cells and its corporation with the canonical Fanconi anemia (FA)/BRCA pathway remain unclear. Here we show that the NEIL3 and the FA/BRCA pathways are non-epistatic in psoralen-ICL repair. The NEIL3 pathway is the major pathway for repairing psoralen-ICL, and the FA/BRCA pathway is only activated when NEIL3 is not present. Mechanistically, NEIL3 is recruited to psoralen-ICL in a rapid, PARP-dependent manner. Importantly, the NEIL3 pathway repairs psoralen-ICLs without generating double-strand breaks (DSBs), unlike the FA/BRCA pathway. In addition, we found that the RUVBL1/2 complex physically interact with NEIL3 and function within the NEIL3 pathway in psoralen-ICL repair. Moreover, TRAIP is important for the recruitment of NEIL3 but not FANCD2, and knockdown of TRAIP promotes FA/BRCA pathway activation. Interestingly, TRAIP is non-epistatic with both NEIL3 and FA pathways in psoralen-ICL repair, suggesting that TRAIP may function upstream of the two pathways. Taken together, the NEIL3 pathway is the major pathway to repair psoralen-ICL through a unique DSB-free mechanism in human cells.

Styles APA, Harvard, Vancouver, ISO, etc.

43

Saini, Neeraj Y., Romil Patel, Ankur Varma, Qaiser Bashir, Omar Hasan, Ruby Delgado, Gabriela Rondon et al. « Long-Term Durable Responses after Autologous Stem Cell Transplantation in POEMS Syndrome ». Blood 132, Supplement 1 (29 novembre 2018) : 4606. http://dx.doi.org/10.1182/blood-2018-99-115710.

Texte intégral

Résumé :

Abstract Abstract: Background: POEMS syndrome is a constellation of symptoms of polyradiculoneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes. Other features often present in this syndrome include papilledema, extravascular volume overload, sclerotic bone lesions, Castleman disease, high vascular endothelial growth factor (VEGF) levels and thrombocytosis/polycythemia. The standard of care has not been established in the management of the disease. We had previously reported on the role of auto-HCT in a smaller cohort of POEMS patients at our institution1. Here, we present an updated analysis in a larger cohort of POEMS patients who underwent auto-HCT. Methods: We retrospectively reviewed the outcomes of POEMS patients who underwent auto-HCT at our institution from the period of January, 1999, through June, 2018. The Kaplan-Meier method was used to caculate progression-free survival (PFS) and overall survival (OS). Hematologic response was defined as per the International Myeloma Working Group (IMWG) criteria. OS was defined as the duration from the date of transplant to death or last date of follow-up in alive patients. PFS was defined as the duration from the date of transplant to either progressive disease or death, whichever occurred first. Results: 16 patients (13 males, 3 females) with POEMS syndrome received a total of 17 auto-HCTs. One patient underwent auto-HCT two times for multiple relapses. The median age at auto-HCT was 48 years (range: 18-75). The median time from diagnosis to auto-HCT was 15 months (2-141 months). All 16 (100%) patients had peripheral neuropathy and monoclonal gammopathy: IgG lambda in 7, IgA lambda in 6, IgG kappa in 2 and light chain in 1 patient. Other features were: osteosclerotic bone lesions in 13 (81%), endocrinopathy in 10 (69%), skin involvement in 8 (50%) and extravascular fluid overload in 7 (44%). Three (18%) patients had biopsy-proven co-existent Castleman disease. Among patients with available data (n=7), the mean serum VEGF level pre-transplant was 389 pg/ml (268-1622). The median HCT-CI (comorbidity index) score available for 15 patients was 2 (range 0-7). The median number of chemotherapies received before the transplant was 1 (range 1-3). Table 1 summarizes the prior systemic chemotherapies received before auto-HCT. Two patients also received plasmapheresis, and eight patients received radiation therapy for bone disease. The mobilization regimens used for collecting peripheral blood stem cells were granulocyte colony-stimulating factor (G-CSF) alone, cyclophosphamide+G-CSF and G-CSf+plerixafor in 16, 2 and one patient, respectively. The median number of CD34+ stem cells collected was 3.43 X 106 cells/kg (range 1.73 - 6.5). The overall response rate, as per the IMWG criteria, for the entire cohort was 94% (16/17): 5 (29.4%) CR, 4 (23.5%) nCR, 1 (5.8%) VGPR, and 6 (35.2%) PR. The mean serum VEGF levels improved from 389 pg/ml before transplant to a level of 35 pg/ml (31-86) post-transplant. Engraftment syndrome was seen only in 1 patient who required corticosteroid use. One-year transplant-related mortality was 0%. Median follow-up among surviving patients is 52 months (5-120 months). The median PFS and OS have not been reached yet. All 16 patients had a complete or partial resolution of their clinical symptoms after auto-HCT. 4-year PFS and OS rate for the entire cohort is 80.2% and 100% respectively. At ten years, PFS and OS rate is 59.4% and 80% respectively. Fourteen out of 16 patients were alive at the time of the last follow-up. One patient died six years after his auto-HCT secondary to gastrointestinal bleeding unrelated to his underlying disease, and the second patient died after 11 years post auto-HCT of unknown cause. Conclusions: Upfront Auto-HCT provides durable chemotherapy free remission and significant clinical improvement in patients with POEMS syndrome. References: Patel, K. et al. Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome. Bone marrow transplantation49, 465-6 (2014). Figure. Figure. Disclosures Thomas: Acerta Pharma: Research Funding; Amgen Inc: Research Funding; Bristol Myers Squibb Inc.: Research Funding; Celgene: Research Funding; Array Pharma: Research Funding. Lee:Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies Corporation: Consultancy; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Chugai Biopharmaceuticals: Consultancy; Takeda Oncology: Consultancy, Membership on an entity's Board of Directors or advisory committees; Kite Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees. Orlowski:Poseida: Research Funding; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Genentech: Consultancy; Janssen Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees; BioTheryX, Inc: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Consultancy; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Millenium Pharmaceuticals: Consultancy, Research Funding. Champlin:Sanofi: Research Funding; Otsuka: Research Funding. Patel:Takeda: Research Funding; Poseida Therapeutics, Inc.: Research Funding; Abbvie: Research Funding; Celgene: Research Funding.

Styles APA, Harvard, Vancouver, ISO, etc.

44

Mayer-Foulkes, David A. « A Survey of Macro Damages from Non-Communicable Chronic Diseases : Another Challenge for Global Governance ». Global Economy Journal 11, n^o 1 (mars 2011) : 1850220. http://dx.doi.org/10.2202/1524-5861.1725.

Texte intégral

Résumé :

Non-communicable chronic diseases (NCDs) are currently the largest global cause of adult mortality, one of the principal burdens of disease in developed and underdeveloped countries. Their main causes are well known, tobacco use, unhealthy diet, physical inactivity and the harmful use of alcohol. The prevalence of these risk factors is directly related to the activities of transnational corporations (TNCs). For example, just the TNC budgets dedicated to advertising risky consumption are larger than the budget of the World Health Organization. A literature survey shows that NCDs have important long-term macroeconomic impacts, whose detailed evaluation has only just begun. The sheer burden on the working and aged population implies strong impacts on labor, saving and investment, as well as increased human capital depreciation. These will all impact long-term economic growth. It is a research priority to quantify these impacts. However, in the context of globalization, NCD is developing faster than its rigorous analysis. Research results show that what is needed is preventive action. This requires a global institutional framework capable of controlling NCD risk factors, which can also promote health and economic growth in general. Developing legal mechanisms to slow the negative impact of the deficient nutrition transition would be a step in that direction. Global markets need to be balanced with global governance holding TNCs responsible for their impact, promoting cooperative solutions when available, and taxing them so that they carry their fair share of social weight.

Styles APA, Harvard, Vancouver, ISO, etc.

45

Dawson, Melanie V. « Ruiz de Burton's Emotional Landscape : Property and Feeling in The Squatter and the Don ». Nineteenth-Century Literature 63, n^o 1 (1 juin 2008) : 41–72. http://dx.doi.org/10.1525/ncl.2008.63.1.41.

Texte intégral

Résumé :

Abstract This essay argues that Maríía Amparo Ruiz de Burton's 1885 novel The Squatter and the Don combines elements of realism and sentimentalism, articulating a realist mode of sympathy that is directed toward the novel's Californio characters. As U.S. citizens who are dispossessed of property and citizenship rights in the wake of the Mexican American War, the Californios register various forms of personal and material loss, albeit analytically and self-consciously. Through the invocation of hybrid emotions, which carry the cultural inflections of both Anglo and Californio traditions, Ruiz de Burton's novel enriches a critical understanding of realism's intervention in a contentious late-nineteenth-century debate about difference in relation to U.S. national and racial identities. Moreover, the novel undercuts a mode of realism devoted to scenic (and, hence, material) detail. By presenting emotional rather than scenic vistas and by highlighting familial and communal bonds in contrast to an exaggerated, capitalist attachment to property (amply demonstrated by the novel's squatter characters), The Squatter and the Don presents affect as a means of understanding the structures of citizenship neglected by U.S. corporations, land commissions, and citizens who colonize California and claim it on behalf of a capitalist nation.

Styles APA, Harvard, Vancouver, ISO, etc.

46

Cavo, Michele, Luciano Masini, Igor W. Blau, Miguel T. Hernandez, Renato Zambello, Paolo de Fabritiis, Christian Berthou et al. « Post-Approval Safety Study (PASS) of Lenalidomide Compared with Other Treatments in Patients with Relapsed or Refractory Multiple Myeloma ». Blood 118, n^o 21 (18 novembre 2011) : 1867. http://dx.doi.org/10.1182/blood.v118.21.1867.1867.

Texte intégral

Résumé :

Abstract Abstract 1867 Background: In recent years, there have been major advances in the treatment of multiple myeloma (MM) as patients now have treatment options that greatly improve clinical outcomes. Many publications have described the safety of anti-myeloma drugs in the clinical trial setting. However, very few have addressed the issue of tolerability of these agents in a real-world clinical setting. Lenalidomide is an effective treatment option for MM and is currently approved by the EMA and US FDA for the treatment of MM patients who have received at least 1 prior therapy. Here we analyze the tolerability of 3 common novel agent-based anti-myeloma therapies in daily clinical practice. Methods: This observational post-authorization safety study was designed to characterize the safety profile of lenalidomide and to compare the incidence of adverse events (AE) with those occurring in patients receiving other anti-myeloma treatments. Patients entering the study had previously received at least 1 prior therapy and were commencing a new treatment for their relapsed/refractory MM (RRMM). Patients were enrolled into the Lenalidomide Cohort (lenalidomide plus dexamethasone) or the Background Cohort (all other treatments) based on investigator's discretion. Thromboprophylaxis was allowed, but not required. Results: As of July 2011, 2201 RRMM patients in 265 institutions in 17 European countries were enrolled. 1500 received lenalidomide, 538 bortezomib, 90 thalidomide, and 73 received other therapies or had missing data. 75 patients from the Background Cohort crossed over to receive lenalidomide. Median follow-up was 20.7 weeks (range, 0.1–125.7 weeks). Overall, the median age was 69 years (range, 29–92) and 55% were male. Most patients had a good performance status (ECOG 0–1) but 18% had an ECOG score of 2–4. The median number of previous treatment lines was 2 (1–6), 51.5% had 2 previous lines and 24% had 3 or more. Baseline characteristics across treatment groups were similar. Patients receiving lenalidomide had a median treatment duration of 4.4 months; patients receiving bortezomib and thalidomide had 3.4 months and 3.7 months, respectively. NCI grade 3/4, serious and life threatening AEs are presented in the table. Venous thromboembolism was experienced in 5% of lenalidomide-treated patients (3% had grade 3/4); 0.7% of bortezomib-treated patients (0.6% had grade 3/4); 1 (1%) thalidomide-treated patient had grade 3/4. Peripheral neuropathy was observed in 10% of lenalidomide-treated patients (1% had grade 3/4); 28% of bortezomib-treated patients (4% had grade 3/4); and 21% of thalidomide-treated patients (2% had grade 3/4). Ten (0.5%) invasive second primary malignancies (SPM) were reported across all treatment groups; 5/1500 (0.3%) patients treated with lenalidomide, 4/538 (0.7%) with bortezomib, and 1/90 (1%) with thalidomide. Three cases of second primary hematologic malignancies (lenalidomide, 2; bortezomib, 1; thalidomide, none) and 7 cases of second primary solid tumors (lenalidomide, 3; bortezomib, 3; thalidomide, 1) were observed. Additionally in the lenalidomide group, 1 patient each developed a non-invasive basal cell carcinoma and a non-invasive fibrous histiocytoma. All of these patients were heavily pre-treated and most had received autologous stem cell transplantation to support high-dose melphalan during the course of their disease. 51% of patients in the lenalidomide group discontinued therapy while 65% and 71% discontinued bortezomib and thalidomide treatments, respectively. Primary reasons for discontinuation were adverse events (lenalidomide, 13%; bortezomib, 14%; thalidomide, 18%) and disease progression (lenalidomide, 15%; bortezomib, 13%; thalidomide, 17%). Overall, 1% of patients died due to an adverse event suspected to be related to drug (lenalidomide, 1%; bortezomib, 0%; thalidomide, 1%). Conclusion: Consistent with previous reports, lenalidomide is generally well tolerated. With the exception of peripheral neuropathy, adverse events in this group of patients treated in daily clinical practice appeared similar across treatment groups. Disclosures: Cavo: Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene Corporation: Honoraria, Membership on an entity's Board of Directors or advisory committees; Millennium Pharmaceuticals: Honoraria, Membership on an entity's Board of Directors or advisory committees. Symeonidis:Novartis Oncology: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Celgene Corporation: Consultancy, Research Funding; Genzyme: Research Funding; Pfizer: Research Funding; Gilead: Consultancy, Research Funding. Bird:Celgene Corporation: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria; Genzyme: Membership on an entity's Board of Directors or advisory committees. Bacon:Celgene Corporation: Employment. Rosettani:Celgene Corporation: Employment. Kueenburg:Celgene Corporation: Employment. Minton:Celgene Corporation: Employment, Equity Ownership.

Styles APA, Harvard, Vancouver, ISO, etc.

47

Reich, Noa. « Seeing “No Guiltless Minds” ». Nineteenth-Century Literature 73, n^o 1 (1 juin 2018) : 30–67. http://dx.doi.org/10.1525/ncl.2018.73.1.30.

Texte intégral

Résumé :

Noa Reich, “Seeing ‘No Guiltless Minds’: Inheritance and Liability in Wilkie Collins’s Armadale” (pp. 30–67) This essay suggests that the articulation of inherited guilt as a type of liability in Wilkie Collins’s Armadale (1866) invites us to reframe inheritance as central both to the Victorian credit economy and to the period’s fictional engagements with the effects of this economy. I begin by examining mid-nineteenth-century legal and political debates about limited corporate liability and estate debts, as well as legal theorist Henry Sumner Maine’s account of succession in Ancient Law (1861), which rests on an analogy between the family and the corporation. With their tropes of transmitted guilt, these discussions point to anxieties arising from the law’s construction of inherited identity as simultaneously individual and intergenerational, a paradox that both refracts and challenges nineteenth-century liberal contractual notions of identity. Armadale explores these issues through its depiction of the testator-heir dynamic as indeterminately singular and double, its association of inheritance with speculative ventures and impersonation, and its vacillation between affirming and limiting intergenerational liability. But it also fosters an alternative, mediating form of responsibility, which I call vicarious liability: a substitutive, imaginative liability both prompted and reinforced by the novel’s competing narrative perspectives and shifting or ambiguous focalization, as well as its embedded letters, diaries, and the depiction of reading as a path to identification with another’s guilt. Armadale’s take on inheritance may thus be read as a proposal for what the novel itself offers a hyper-contractual modernity: a framework for engaging in vicarious experiences of liability.

Styles APA, Harvard, Vancouver, ISO, etc.

48

Fan, Xiaonan, Jingyang Li et Ye Wang. « The Driving Factors of Innovation Quality of Agricultural Enterprises—A Study Based on NCA and fsQCA Methods ». Sustainability 15, n^o 3 (17 janvier 2023) : 1809. http://dx.doi.org/10.3390/su15031809.

Texte intégral

Résumé :

Agricultural product processing enterprises are a significant cornerstone to support the improvement of agricultural economy. How to reinforce the main position of innovation of agricultural product processing enterprises, gather innovation factors, and improve the innovation quality of enterprises is an important question to answer. Based on the technology–organization–environment (TOE) theory , dynamic capability theory, organizational learning theory, and sustainable business model theory, this essay develops a comprehensive system for sustainable innovation quality, takes 36 agricultural processing enterprises in Liaoning province, China, as research samples, and applies necessary condition analysis (NCA) and fuzzy set qualitative comparative analysis (fsQCA) to recognize the driving factors of innovation quality in agricultural processing enterprises. The results show that: (1) a single driving factor is not a necessary condition for high innovation quality, but entrepreneurship and the enhancement of green technology capability have a more universal role in producing high innovation quality in agricultural product processing corporations; (2) a combination of four paths enables internal and external factors to couple and interact with each other to achieve high sustainable innovation quality in agricultural processing enterprises in Liaoning province, which can be further divided into two major categories. The first category is “entrepreneurship–government support driven path”, in which entrepreneurship and government support are the main drivers, supplemented by green technology capability, organizational learning, and market demand; the second category is “green technology capability–market demand driven path”, in which green technology capability and market demand are the main drivers, supplemented by organizational learning, entrepreneurship, and government support. This paper also identifies seven conditional configurations that lead to non-high innovation quality, which can be categorized as the technology-inhibited type, entrepreneurship-deprived type, and government and market-driven type. The discoveries of this paper have significant hypothetical and practical value for improving the innovation quality of agricultural enterprises.

Styles APA, Harvard, Vancouver, ISO, etc.

49

Hendrick, Franklin, Amy J. Davidoff, Amer M. Zeidan, Steven D. Gore et Maria R. Baer. « Association Between FDA Safety Warnings, CMS Coverage Restrictions and Adherence to Guidelines for ESA Use in Patients with Myelodysplastic Syndromes ». Blood 120, n^o 21 (16 novembre 2012) : 971. http://dx.doi.org/10.1182/blood.v120.21.971.971.

Texte intégral

Résumé :

Abstract Abstract 971 Background: Erythopoiesis-stimulating agents (ESAs) are used to treat anemia associated with myelodysplastic syndromes (MDS) as an off-label indication. Our prior research demonstrated poor adherence to MDS treatment guidelines in the management of US Medicare-insured patients. These guidelines include measuring serum erythropoietin (EPO) levels to predict likelihood of response to ESAs, initiating ESAs before the patient is transfusion-dependent (TD) and determining ESA response following an 8-week administration. Concerns with regard to ESA adverse events including thromboembolic events and tumor progression led the U.S. Food and Drug Administration (FDA) to release safety alerts and mandate label changes in early 2007. In a rare move, the Centers for Medicare and Medicaid Services (CMS) implemented a National Coverage Determination (NCD) in August ‘07, dramatically restricting ESA coverage based on specific clinical parameters (e.g. baseline hemoglobin). Market-level studies indicate substantial reductions in ESA use for management of chemotherapy-related anemia in response to the CMS NCD. As ESA use in MDS patients was not directly targeted by the NCD, we sought to examine whether ESA use changed following these actions. Methods: Using 100% Medicare enrollment and claims data from 2004–2008, we selected beneficiaries assigned MDS diagnostic codes following a bone marrow aspirate procedure. Patients were observed from diagnosis until death or end of study. Through procedure codes on claims, we determined the receipt of any ESA within 6 months of MDS diagnosis, whether serum EPO level was measured prior to ESA initiation, whether treatment was of therapeutic duration (>=8 weeks), and transfusion use during the 7 weeks prior to and including the week of ESA initiation. Logistic regression models tested the effect of time (half-year increments pre-post the August ‘07 CMS NCD implementation), controlling for demographics, health status, and supplemental insurance. Results: The sample included 36,537 MDS patients; of whom 23,351 (64%) received ESAs. Figure 1 shows trends in ESA use and consistency with recommended practices. Regression analysis indicated that, relative to Jan-June 2005, ESA use increased through ‘06 (OR 1.22, 95% CI 1.12, 1.33), and then declined beginning in August ‘07 (OR 0.71, CI 0.65, 0.77). Assessment of serum EPO levels increased beginning in January ‘06, preceding the FDA/CMS actions. ESA use increased among transfusion users throughout the study period (Jan-June '08 OR 1.59, CI 1.43, 1.77), and the proportion of patients receiving therapeutic-duration episodes began to decline in Jan ‘07 (OR 0.82, CI 0.73–0.91). Conclusions: These results suggest a mixed pattern of change in the face of the FDA safety warnings and CMS NCD in MDS. ESA use was increasing prior to the CMS NCD, but that trend reversed at the time of the NCD. Among patients receiving ESAs, there was an increase in serum EPO determination prior to ESA initiation, however it seems to have preceded the FDA and CMS policy changes. Tthese results also suggest that after the CMS NCD, physicians may have delayed initiation of ESAs until patients were using transfusions, and administered shorter episodes of treatment. Thus policy changes, which were not directed at MDS, may have had a negative impact on adherence to recommended practices. These findings reinforce the importance of monitoring changes in clinical practice after a change in coverage policy, in order to identify possible unintended consequences for quality or access to care. Disclosures: Off Label Use: Erythropoiesis-Stimulating Agents (ESAs) are indicated for the treatment of anemia associated with chronic renal failure and myelosuppressive anticancer chemotherapy in solid tumors, multiple myeloma, lymphoma, and lymphocytic leukemia. The current research explores the use of ESAs as an off-label indication within patients diagnosed with myelodysplastic syndrome. Davidoff:GlaskoSmithKline: Research Funding; National Institutes of Health: Research Funding; Celgene: Research Funding; Novartis: Research Funding. Gore:Celgene Corporation: Consultancy, Research Funding.

Styles APA, Harvard, Vancouver, ISO, etc.

50

Larocca, Alessandra, Paolo Corradini, Roberto Mina, Nicola Cascavilla, Anna Marina Liberati, Norbert Pescosta, Maria Teresa Petrucci et al. « Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients : Analysis of the Phase II Randomized Unito-EMN10 Study ». Blood 134, Supplement_1 (13 novembre 2019) : 3195. http://dx.doi.org/10.1182/blood-2019-124388.

Texte intégral

Résumé :

INTRODUCTION. Bortezomib- and/or lenalidomide-based combinations are standard initial approaches in transplant (ASCT) ineligible NDMM. Different studies confirmed the advantages of continuous treatment. Despite the benefits of bortezomib maintenance, the parenteral administration and the risk of peripheral neuropathy (PN) limit its long-term use. The oral proteasome inhibitor (PI) Ixazomib plus Lenalidomide-dexamethasone was effective and well tolerated at diagnosis or relapse. The need for a convenient and well tolerated PI-based frontline therapy for an extended duration with minimal cumulative toxicity remains an unmet need for the elderly. In this prospective, multicenter, phase II randomized study, we assessed Ixazomib in combination with dexamethasone, Cyclophosphamide, Thalidomide or Bendamustine, followed by Ixazomib maintenance in ASCT-ineligible NDMM. METHODS. NDMM patients (pts) ≥65 years old or younger ASCT-ineligible could be enrolled. Treatment consisted of nine 28-day induction cycles of Ixazomib 4 mg on days 1,8,15 and dexamethasone 40 mg on days 1,8,15,22 (Id) or combined with Cyclophosphamide 300 mg/m2 orally on days 1,8,15 (ICd) or plus Thalidomide 100 mg/day (ITd) or plus Bendamustine 75 mg/m2 iv on days 1,8 (IBd); followed by maintenance with Ixazomib 4 mg on days 1,8,15 until progression. Because the study included the novel drug Ixazomib, dual stopping rules combining efficacy (at least very good partial response [VGPR] rate), and safety (predefined toxicity possibly related to Ixazomib) were planned and analyzed in a cohort of 5 patients in each arm during the first 4 cycles. Here we report the results of the cohort analysis during the first 4 cycles and the efficacy and safety analysis during induction treatment. RESULTS. In February 2017, the protocol was amended due to a low enrolment and the IBd arm, the only one including an iv drug, was closed. After closing this arm, all the other all oral arms continued the enrolment. Overall, 175 pts were enrolled (Id 42, ICd 61, ITd 61, and IBd 11 pts) and 171 pts started treatment. Median age was 74 years, 20% of pts had high risk cytogenetics, 44% were fit, 30% intermediate and 26% frail, according to the IMWG frailty score. Median follow-up was 13.2 months (IQR 8.9-20.7). During the first 4 cycles, at least VGPR rate was 24% with Id, 33% with ICd, 31% with ITd and 18% with IBd. In March 2018, after the analysis of the 4th cohort, the Id arm was closed due to high risk of inefficacy. Overall response rate (ORR) during induction was 73%, VGPR was 39%. ≥VGPR rates were 24% in Id, 48% in ICd, 43% in ITd and 27% in IBd. Median time to first response was 2.4 and to the best response 4 months. Responses were comparable according to cytogenetics: in high risk pts, ORR was 77%, ≥VGPR 46% and ≥nCR 17% as compared to 71%, 36% and 18% in standard risk pts (p=0.53, p=0.33 and p=1, respectively). Response rates were also comparable according to frailty status: in frail pts, ORR was 73%, ≥VGPR 36% and ≥nCR 11% as compared to 75%, 40% and 17% in intermediate and 70%, 40% and 22% in fit pts (p=0.78, p=0.90 and p=0.32, respectively). Median number of induction cycles was 9 (IQR 5-9); 93 (53%) pts completed induction treatment and 14 (8%) pts are still on induction treatment. During the first 4 cycles, hematologic toxicity was limited, and non-hematologic toxicity manageable. The most frequent G3-4 adverse event (AE) was rash in ITd arm (11%); discontinuation rate due to toxicity was 6%. During induction, the rate of at least 1 hematologic G≥3 AE was 11% and at least 1 non-hematologic G≥3 AE was 44%. The most frequent G≥3 AEs were neutropenia (8%), gastrointestinal (9%), infections (11%), neurologic (11%) and dermatologic (6%). G3-4 thrombocytopenia (3%) and PN (5%) were limited. Ixazomib dose reduction due to AEs was required in 15% of pts. The rate of non-hematologic AEs was slightly higher in ITd arm (37% in Id, 37% in ICd, 53% in ITd, 55% in IBd). Early death rate (<60 days from start therapy) was 1%. CONCLUSIONS. ITd and ICd are convenient all-oral induction regimens for ASCT-ineligible NDMM, confirming an improved efficacy of a triplet vs a doublet combination, also in intermediate and frail patients. Id showed lower efficacy, thus suggesting a possible effect of the dose of Ixazomib or the absence of a third drug. Treatment was feasible, with limited toxicity and low discontinuation rate due to AEs, although ITd induced a slightly higher toxicity, but mainly attributable to Thalidomide. Disclosures Larocca: Amgen: Honoraria; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees. Corradini:Servier: Honoraria; Amgen: Honoraria; Gilead: Honoraria, Other: Travel Costs; Takeda: Honoraria, Other: Travel Costs; BMS: Other: Travel Costs; Kite: Honoraria; Novartis: Honoraria, Other: Travel Costs; Roche: Honoraria; Sanofi: Honoraria; KiowaKirin: Honoraria; Jazz Pharmaceutics: Honoraria; Daiichi Sankyo: Honoraria; Janssen: Honoraria, Other: Travel Costs; AbbVie: Consultancy, Honoraria, Other: Travel Costs; Celgene: Honoraria, Other: Travel Costs. Mina:Amgen: Honoraria; Celgene: Honoraria; Janssen: Honoraria. Liberati:Bristol-Myers Squibb: Honoraria; Roche: Other: Clinical trial support; Takeda: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees, Other: Clinical trial support; Janssen: Honoraria; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Clinical trial support; Servier: Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Consultancy; Celgene: Honoraria, Other: Clinical trial support; Novartis: Other: Clinical trial support. Petrucci:Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen-Cilag: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees. Patriarca:Celgene: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees. Zambello:Janssen: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees. Belotti:Amgen: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees. Cellini:Amgen: Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria; Janssen: Honoraria. Galli:Takeda: Honoraria; Leadiant (Sigma-Tau): Honoraria; Janssen: Honoraria; Celgene: Honoraria; Bristol-Myers Squibb: Honoraria. Aquino:Celgene: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees. De Sabbata:Janssen: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees. Ballanti:Bristol-Myers Squibb: Honoraria; Janssen: Honoraria; Celgene: Honoraria; Amgen: Honoraria. Offidani:Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees. Boccadoro:Janssen: Honoraria, Research Funding; Sanofi: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Bristol-Myers Squibb: Honoraria, Research Funding; AbbVie: Honoraria; Mundipharma: Research Funding; Celgene: Honoraria, Research Funding; Amgen: Honoraria, Research Funding. Bringhen:Celgene Corporation: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Karyopharm: Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy; Bristol-Myers Squibb: Honoraria. OffLabel Disclosure: The presentation includes discussion of off-label use of a drug or drugs for the treatment of multiple myeloma.

Styles APA, Harvard, Vancouver, ISO, etc.

Articles de revues sur le sujet « NCR Corporation »

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres